
-DOCSTART- -X- -X- O

Flecainide	NNP	O	O
block	NN	O	O
of	IN	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
current	JJ	O	O
(	(	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
)	)	O	O
was	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
wild-type	NN	O	O
(	(	O	O
WT	NNP	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
long	JJ	O	B-enzyme
QT	NNP	O	I-enzyme
syndrome	NN	O	O
3	CD	O	O
(	(	O	O
LQT3	NNP	O	O
)	)	O	O
sodium	NN	O	B-SUBSTRATE
channel	NN	O	O
alpha	NN	O	O
subunit	NN	O	O
mutation	NN	O	O
with	IN	O	O
three	CD	O	O
amino	NN	O	O
acids	NNS	O	O
deleted	VBD	O	O
(	(	O	O
DeltaKPQ	NNP	O	O
)	)	O	O
stably	RB	O	O
transfected	VBD	O	O
into	IN	O	O
human	JJ	O	O
embryonic	JJ	O	O
kidney	NN	O	O
293	CD	O	O
cells	NNS	O	O
using	VBG	O	O
whole-cell	NN	O	O
,	,	O	O
patch-clamp	JJ	O	O
recordings	NNS	O	O
.	.	O	O

Flecainide	NNP	O	O
(	(	O	O
1-300	JJ	O	O
mM	NN	O	O
)	)	O	O
caused	VBD	O	O
tonic	JJ	O	O
and	CC	O	O
use-dependent	JJ	O	O
block	NN	O	O
(	(	O	O
UDB	NNP	O	O
)	)	O	O
of	IN	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
concentration-dependent	JJ	O	O
manner	NN	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
WT	NNP	O	O
,	,	O	O
DeltaKPQ	NNP	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
was	VBD	O	O
more	RBR	O	O
sensitive	JJ	O	O
to	TO	O	O
flecainide	VB	O	O
,	,	O	O
and	CC	O	O
flecainide	RB	O	O
preferentially	RB	O	O
inhibited	VBN	O	O
late	JJ	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
(	(	O	O
mean	JJ	O	O
current	JJ	O	O
between	IN	O	O
20	CD	O	O
and	CC	O	O
23.5	CD	O	O
ms	NN	O	O
after	IN	O	O
depolarization	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
peak	NN	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
value	NN	O	O
of	IN	O	O
peak	NN	O	O
and	CC	O	O
late	JJ	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
for	IN	O	O
WT	NNP	O	O
was	VBD	O	O
127	CD	O	O
+/-	JJ	O	O
6	CD	O	O
and	CC	O	O
44	CD	O	O
+/-	JJ	O	O
2	CD	O	O
microM	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
and	CC	O	O
for	IN	O	O
DeltaKPQ	NNP	O	O
was	VBD	O	O
80	CD	O	O
+/-	JJ	O	O
9	CD	O	O
and	CC	O	O
19	CD	O	O
+/-	JJ	O	O
2	CD	O	O
microM	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
31	CD	O	O
)	)	O	O
respectively	RB	O	O
.	.	O	O

UDB	NNP	O	O
of	IN	O	O
peak	NN	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
was	VBD	O	O
greater	JJR	O	O
and	CC	O	O
developed	VBD	O	O
more	JJR	O	O
slowly	RB	O	O
during	IN	O	O
pulse	JJ	O	O
trains	NNS	O	O
for	IN	O	O
DeltaKPQ	NNP	O	O
than	IN	O	O
for	IN	O	O
WT	NNP	O	O
.	.	O	O

The	DT	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
value	NN	O	O
for	IN	O	O
UDB	NNP	O	O
of	IN	O	O
peak	NN	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
for	IN	O	O
WT	NNP	O	O
was	VBD	O	O
29	CD	O	O
+/-	JJ	O	O
4	CD	O	O
microM	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
and	CC	O	O
for	IN	O	O
DeltaKPQ	NNP	O	O
was	VBD	O	O
11	CD	O	O
+/-	JJ	O	O
1	CD	O	O
microM	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
26	CD	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
DeltaKPQ	NNP	O	O
,	,	O	O
UDB	NNP	O	O
of	IN	O	O
late	JJ	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
was	VBD	O	O
greater	JJR	O	O
than	IN	O	O
for	IN	O	O
peak	NN	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
.	.	O	O

Recovery	NN	O	O
from	IN	O	O
block	NN	O	O
was	VBD	O	O
slower	JJR	O	O
for	IN	O	O
DeltaKPQ	NNP	O	O
than	IN	O	O
for	IN	O	O
WT	NNP	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
DeltaKPQ	NNP	O	O
interacts	VBZ	O	O
differently	RB	O	O
with	IN	O	O
flecainide	NN	O	O
than	IN	O	O
with	IN	O	O
WT	NNP	O	O
,	,	O	O
leading	VBG	O	O
to	TO	O	O
increased	VBN	O	O
block	NN	O	O
and	CC	O	O
slowed	VBD	O	O
recovery	NN	O	O
,	,	O	O
especially	RB	O	O
for	IN	O	O
late	JJ	O	O
I	PRP	O	O
(	(	O	O
Na	NNP	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
provide	VBP	O	O
insights	NNS	O	O
into	IN	O	O
mechanisms	NNS	O	O
for	IN	O	O
flecainide	JJ	O	O
block	NN	O	O
and	CC	O	O
provide	VB	O	O
a	DT	O	O
rationale	NN	O	O
at	IN	O	O
the	DT	O	O
cellular	JJ	O	O
and	CC	O	O
molecular	JJ	O	O
level	NN	O	O
that	WDT	O	O
open	JJ	O	O
channel	NNS	O	O
block	NN	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
pharmacological	JJ	O	O
property	NN	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
LQT3	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
polyamines	NNS	O	O
spermidine	NN	O	O
,	,	O	O
spermine	NN	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
precursor	NN	O	O
putrescine	NN	O	O
are	VBP	O	O
essential	JJ	O	O
for	IN	O	O
cell	NN	O	O
growth	NN	O	O
and	CC	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
excessive	JJ	O	O
accumulation	NN	O	O
of	IN	O	O
polyamines	NNS	O	O
favors	NNS	O	O
either	CC	O	O
malignant	JJ	O	O
transformation	NN	O	O
or	CC	O	O
apoptosis	NN	O	O
,	,	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
cell	NN	O	O
type	NN	O	O
and	CC	O	O
the	DT	O	O
stimulus	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
examines	VBZ	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
polyamines	NNS	O	O
in	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
apoptosis	NN	O	O
by	IN	O	O
the	DT	O	O
DNA	NNP	O	O
topoisomerase	NN	O	O
I	PRP	O	O
inhibitor	VBP	O	O
,	,	O	O
camptothecin	NN	O	O
.	.	O	O

In	IN	O	O
IEC-6	NNP	O	O
cells	NNS	O	O
,	,	O	O
camptothecin	NN	O	O
induced	VBD	O	O
apoptosis	NN	O	O
within	IN	O	O
6	CD	O	O
h	NNS	O	O
,	,	O	O
accompanied	VBN	O	O
by	IN	O	O
detachment	NN	O	O
of	IN	O	O
cells	NNS	O	O
.	.	O	O

Detached	NNP	O	O
cells	NNS	O	O
showed	VBD	O	O
DNA	NNP	O	O
laddering	NN	O	O
and	CC	O	O
caspase	NN	O	O
3	CD	O	O
induction	NN	O	O
,	,	O	O
characteristic	JJ	O	O
features	NNS	O	O
of	IN	O	O
apoptosis	NN	O	O
.	.	O	O

Depletion	NN	O	O
of	IN	O	O
putrescine	NN	O	B-PRODUCT-OF
,	,	O	O
spermidine	NN	O	B-PRODUCT-OF
,	,	O	O
and	CC	O	O
spermine	NN	O	B-PRODUCT-OF
by	IN	O	O
DL-alpha-difluoromethylornithine	NNP	O	O
(	(	O	O
DFMO	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
specific	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
ornithine	JJ	O	B-enzyme
decarboxylase	NN	O	I-enzyme
(	(	O	O
ODC	NNP	O	B-enzyme
)	)	O	O
that	WDT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
rate-limiting	JJ	O	O
enzyme	NN	O	O
for	IN	O	O
polyamine	JJ	O	O
biosynthesis	NN	O	O
,	,	O	O
decreased	VBD	O	O
the	DT	O	O
apoptotic	JJ	O	O
index	NN	O	O
.	.	O	O

Delayed	VBN	O	O
apoptosis	NN	O	O
was	VBD	O	O
accompanied	VBN	O	O
by	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
caspase	NN	O	O
3	CD	O	O
activity	NN	O	O
in	IN	O	O
polyamine-depleted	JJ	O	O
cells	NNS	O	O
.	.	O	O

Addition	NN	O	O
of	IN	O	O
putrescine	NN	O	O
restored	VBN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
apoptosis	NN	O	O
as	IN	O	O
indicated	VBN	O	O
by	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
detached	JJ	O	O
cells	NNS	O	O
and	CC	O	O
caspase	VB	O	O
3	CD	O	O
activity	NN	O	O
.	.	O	O

Polyamine	NNP	O	O
depletion	NN	O	O
did	VBD	O	O
not	RB	O	O
change	VB	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
caspase	NN	O	O
3	CD	O	O
protein	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
S-adenosylmethionine	NNP	O	B-enzyme
decarboxylase	NN	O	I-enzyme
by	IN	O	O
a	DT	O	O
specific	JJ	O	O
inhibitor	NN	O	O
[	JJ	O	O
diethylglyoxal	JJ	O	O
bis-	NN	O	O
(	(	O	O
guanylhydrazone	NN	O	O
)	)	O	O
;	:	O	O
DEGBG	NNP	O	O
]	NNP	O	O
led	VBD	O	O
to	TO	O	O
depletion	NN	O	O
of	IN	O	O
spermidine	NN	O	B-PRODUCT-OF
and	CC	O	O
spermine	NN	O	B-PRODUCT-OF
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
accumulation	NN	O	O
of	IN	O	O
putrescine	NN	O	O
and	CC	O	O
induction	NN	O	O
of	IN	O	O
ODC	NNP	O	O
.	.	O	O

The	DT	O	O
DEGBG-treated	NNP	O	O
cells	NNS	O	O
showed	VBD	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
apoptosis	NN	O	O
,	,	O	O
suggesting	VBG	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
putrescine	NN	O	O
in	IN	O	O
the	DT	O	O
apoptotic	JJ	O	O
process	NN	O	O
.	.	O	O

Addition	NN	O	O
of	IN	O	O
putrescine	NN	O	O
to	TO	O	O
DFMO-treated	NNP	O	O
cell	NN	O	O
extracts	NNS	O	O
did	VBD	O	O
not	RB	O	O
increase	VB	O	O
caspase	NN	O	O
3	CD	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
above	JJ	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
polyamine	NN	O	O
depletion	NN	O	O
delays	VBZ	O	O
the	DT	O	O
onset	NN	O	O
of	IN	O	O
apoptosis	NN	O	O
in	IN	O	O
IEC-6	NNP	O	O
cells	NNS	O	O
and	CC	O	O
confers	NNS	O	O
protection	NN	O	O
against	IN	O	O
DNA	NNP	O	O
damaging	VBG	O	O
agents	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
polyamines	NNS	O	O
might	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
caspase	NN	O	O
activating	VBG	O	O
signal	JJ	O	O
cascade	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Follicle-stimulating	VBG	O	B-enzyme
hormone	NN	O	I-enzyme
(	(	O	O
FSH	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
a	DT	O	O
dimeric	JJ	O	O
glycoprotein	NN	O	O
synthesized	VBN	O	O
in	IN	O	O
the	DT	O	O
anterior	JJ	O	O
pituitary	JJ	O	O
gland	NN	O	O
,	,	O	O
is	VBZ	O	O
important	JJ	O	O
for	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
sex	NN	O	O
steroids	NNS	O	B-PRODUCT-OF
and	CC	O	O
gametes	NNS	O	O
.	.	O	O

FSH-beta	NNP	O	O
(	(	O	O
FSH	NNP	O	O
beta	NN	O	O
)	)	O	O
and	CC	O	O
FSH	NNP	O	O
receptor	NN	O	O
(	(	O	O
FSHR	NNP	O	O
)	)	O	O
knockout	NN	O	O
mice	NN	O	O
display	NN	O	O
impaired	VBD	O	O
ovarian	JJ	O	O
follicular	NN	O	O
development	NN	O	O
and	CC	O	O
infertility	NN	O	O
in	IN	O	O
females	NNS	O	O
and	CC	O	O
small	JJ	O	O
testes	NNS	O	O
,	,	O	O
oligospermia	NN	O	O
,	,	O	O
and	CC	O	O
fertility	NN	O	O
in	IN	O	O
males	NNS	O	O
.	.	O	O

Humans	NNS	O	O
with	IN	O	O
FSH	NNP	O	B-enzyme
beta	NN	O	I-enzyme
gene	NN	O	O
mutations	NNS	O	O
tend	VBP	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
more	RBR	O	O
severe	JJ	O	O
phenotype	NN	O	O
than	IN	O	O
those	DT	O	O
with	IN	O	O
FSHR	NNP	O	O
gene	NN	O	O
mutations	NNS	O	O
,	,	O	O
although	IN	O	O
infertility	NN	O	O
and	CC	O	O
varying	VBG	O	O
degrees	NNS	O	O
of	IN	O	O
impaired	JJ	O	O
sex	NN	O	O
steroid	JJ	O	B-PRODUCT-OF
production	NN	O	O
occur	NN	O	O
in	IN	O	O
both	DT	O	O
types	NNS	O	O
of	IN	O	O
mutations	NNS	O	O
.	.	O	O

Data	NNS	O	O
from	IN	O	O
human	JJ	O	O
and	CC	O	O
mouse	NN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
FSH	NNP	O	O
beta	NN	O	O
and	CC	O	O
FSHR	NNP	O	O
genes	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
FSH	NNP	O	O
is	VBZ	O	O
necessary	JJ	O	O
for	IN	O	O
normal	JJ	O	O
pubertal	JJ	O	O
development	NN	O	O
and	CC	O	O
fertility	NN	O	O
in	IN	O	O
males	NNS	O	O
and	CC	O	O
females	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Inhibition	NN	O	O
studies	NNS	O	O
have	VBP	O	O
suggested	VBN	O	O
that	IN	O	O
acyl-CoA	JJ	O	O
synthetase	NN	O	O
(	(	O	O
ACS	NNP	O	O
,	,	O	O
EC	NNP	O	O
)	)	O	O
isoforms	NNS	O	O
might	MD	O	O
regulate	VB	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
acyl-CoAs	JJ	O	O
by	IN	O	O
different	JJ	O	O
metabolic	JJ	O	O
pathways	NNS	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
subcellular	JJ	O	O
locations	NNS	O	O
differed	VBD	O	O
for	IN	O	O
each	DT	O	O
of	IN	O	O
the	DT	O	O
three	CD	O	O
ACSs	NNP	O	O
present	NN	O	O
in	IN	O	O
liver	NN	O	O
and	CC	O	O
whether	IN	O	O
these	DT	O	O
isoforms	NNS	O	O
were	VBD	O	O
regulated	VBN	O	O
independently	RB	O	O
,	,	O	O
non-cross-reacting	JJ	O	O
peptide	NN	O	O
antibodies	NNS	O	O
were	VBD	O	O
raised	VBN	O	O
against	IN	O	O
ACS1	NNP	O	O
,	,	O	O
ACS4	NNP	O	O
,	,	O	O
and	CC	O	O
ACS5	NNP	O	O
.	.	O	O

ACS1	NNP	O	O
was	VBD	O	O
identified	VBN	O	O
in	IN	O	O
endoplasmic	JJ	O	O
reticulum	NN	O	O
,	,	O	O
mitochondria-associated	JJ	O	O
membrane	NN	O	O
(	(	O	O
MAM	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
cytosol	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
mitochondria	NNS	O	O
.	.	O	O

ACS4	NNP	O	O
was	VBD	O	O
present	JJ	O	O
primarily	RB	O	O
in	IN	O	O
MAM	NNP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
76-kDa	JJ	O	O
ACS5	NNP	O	O
protein	NN	O	O
was	VBD	O	O
located	VBN	O	O
in	IN	O	O
mitochondrial	JJ	O	O
membrane	NN	O	O
.	.	O	O

Consistent	JJ	O	O
with	IN	O	O
these	DT	O	O
locations	NNS	O	O
,	,	O	O
N-ethylmaleimide	NNP	O	O
,	,	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
ACS4	NNP	O	O
,	,	O	O
inhibited	VBD	O	O
ACS	NNP	O	O
activity	NN	O	O
47	CD	O	O
%	NN	O	O
in	IN	O	O
MAM	NNP	O	O
and	CC	O	O
28	CD	O	O
%	NN	O	O
in	IN	O	O
endoplasmic	JJ	O	O
reticulum	NN	O	O
.	.	O	O

Troglitazone	NN	O	O
,	,	O	O
a	DT	O	O
second	JJ	O	O
ACS4	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
inhibited	JJ	O	O
ACS	NNP	O	O
activity	NN	O	O
<	RB	O	O
10	CD	O	O
%	NN	O	O
in	IN	O	O
microsomes	NNS	O	O
and	CC	O	O
mitochondria	NNS	O	O
and	CC	O	O
45	CD	O	O
%	NN	O	O
in	IN	O	O
MAM	NNP	O	O
.	.	O	O

Triacsin	NNP	O	O
C	NNP	O	O
,	,	O	O
a	DT	O	O
competitive	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
both	DT	O	O
ACS1	NNP	O	O
and	CC	O	O
ACS4	NNP	O	O
,	,	O	O
inhibited	VBD	O	O
ACS	NNP	O	O
activity	NN	O	O
similarly	RB	O	O
in	IN	O	O
endoplasmic	JJ	O	O
reticulum	NN	O	O
,	,	O	O
MAM	NNP	O	O
,	,	O	O
and	CC	O	O
mitochondria	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
a	DT	O	O
hitherto	NN	O	O
unidentified	JJ	O	O
triacsin-sensitive	JJ	O	O
ACS	NNP	O	O
is	VBZ	O	O
present	JJ	O	O
in	IN	O	O
mitochondria	NN	O	O
.	.	O	O

ACS1	NNP	O	O
,	,	O	O
ACS4	NNP	O	O
,	,	O	O
and	CC	O	O
ACS5	NNP	O	O
were	VBD	O	O
regulated	VBN	O	O
independently	RB	O	O
by	IN	O	O
fasting	VBG	O	O
and	CC	O	O
re-feeding	NN	O	O
.	.	O	O

Fasting	VBG	O	O
rats	NNS	O	O
for	IN	O	O
48	CD	O	O
h	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
ACS4	NNP	O	O
protein	NN	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
ACS5	NNP	O	O
.	.	O	O

Re-feeding	JJ	O	O
normal	JJ	O	O
chow	NN	O	O
or	CC	O	O
a	DT	O	O
high	JJ	O	O
sucrose	NN	O	O
diet	NN	O	O
for	IN	O	O
24	CD	O	O
h	NN	O	O
after	IN	O	O
a	DT	O	O
48-h	JJ	O	O
fast	NN	O	O
increased	VBD	O	O
both	DT	O	O
ACS1	NNP	O	O
and	CC	O	O
ACS4	NNP	O	O
protein	VBP	O	O
expression	NN	O	O
1.5-2.0-fold	JJ	O	O
,	,	O	O
consistent	JJ	O	O
with	IN	O	O
inhibition	NN	O	O
studies	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
ACS1	NNP	O	B-enzyme
and	CC	O	O
ACS4	NNP	O	B-enzyme
may	MD	O	O
be	VB	O	O
linked	VBN	O	O
to	TO	O	O
triacylglycerol	VB	O	B-PRODUCT-OF
synthesis	NN	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
the	DT	O	O
data	NN	O	O
suggest	NN	O	O
that	IN	O	O
acyl-CoAs	NN	O	O
may	MD	O	O
be	VB	O	O
functionally	RB	O	O
channeled	VBN	O	O
to	TO	O	O
specific	JJ	O	O
metabolic	JJ	O	O
pathways	NNS	O	O
through	IN	O	O
different	JJ	O	O
ACS	NNP	O	O
isoforms	NNS	O	O
in	IN	O	O
unique	JJ	O	O
subcellular	JJ	O	O
locations	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

AIMS	NNS	O	O
:	:	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
nabumetone	NN	O	O
and	CC	O	O
meloxicam	NN	O	O
,	,	O	O
two	CD	O	O
cyclo-oxygenase-2	NN	O	O
(	(	O	O
COX-2	NNP	O	O
)	)	O	O
preferential	JJ	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	O	O
(	(	O	O
NSAIDs	NNP	O	O
)	)	O	O
,	,	O	O
on	IN	O	O
platelet	JJ	O	O
COX-1	NNP	O	O
activity	NN	O	O
and	CC	O	O
platelet	NN	O	O
function	NN	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
Twelve	NNP	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
(	(	O	O
3	CD	O	O
male	NN	O	O
,	,	O	O
9	CD	O	O
female	NN	O	O
,	,	O	O
median	JJ	O	O
age	NN	O	O
22	CD	O	O
years	NNS	O	O
)	)	O	O
participated	VBD	O	O
in	IN	O	O
an	DT	O	O
open	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
cross-over	JJ	O	O
trial	NN	O	O
of	IN	O	O
nabumetone	NN	O	O
1000	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
vs	JJ	O	O
meloxicam	NN	O	O
7.5	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
during	IN	O	O
1	CD	O	O
week	NN	O	O
with	IN	O	O
2	CD	O	O
weeks	NNS	O	O
wash-out	RB	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
second	JJ	O	O
2	CD	O	O
week	NN	O	O
wash-out	JJ	O	O
period	NN	O	O
,	,	O	O
one	CD	O	O
dose	NN	O	O
of	IN	O	O
indomethacin	JJ	O	O
50	CD	O	O
mg	NN	O	O
was	VBD	O	O
given	VBN	O	O
as	IN	O	O
a	DT	O	O
positive	JJ	O	O
control	NN	O	O
to	TO	O	O
check	VB	O	O
for	IN	O	O
NSAID	NNP	O	O
induced	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
platelet	NN	O	O
function	NN	O	O
.	.	O	O

COX-1	JJ	O	B-enzyme
inhibition	NN	O	O
was	VBD	O	O
measured	VBN	O	O
as	IN	O	O
percentage	NN	O	O
inhibition	NN	O	O
of	IN	O	O
serum	NN	O	O
TXB2	NNP	O	B-PRODUCT-OF
generation	NN	O	O
in	IN	O	O
clotting	VBG	O	O
whole	JJ	O	O
blood	NN	O	O
,	,	O	O
and	CC	O	O
as	IN	O	O
closure	NN	O	O
time	NN	O	O
with	IN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
platelet	NN	O	O
function	NN	O	O
analyser	IN	O	O
PFA-100	NNP	O	O
.	.	O	O

Data	NNS	O	O
are	VBP	O	O
reported	VBN	O	O
as	IN	O	O
median	NN	O	O
with	IN	O	O
range	NN	O	O
.	.	O	O

Paired	VBN	O	O
variables	NNS	O	O
were	VBD	O	O
analysed	VBN	O	O
using	VBG	O	O
Wilcoxons	NNS	O	O
signed	VBD	O	O
rank	JJ	O	O
test	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
TXB2	NNP	O	O
levels	NNS	O	O
decreased	VBN	O	O
significantly	RB	O	O
after	IN	O	O
all	DT	O	O
three	CD	O	O
medications	NNS	O	O
,	,	O	O
but	CC	O	O
percentage	NN	O	O
inhibition	NN	O	O
after	IN	O	O
nabumetone	NN	O	O
and	CC	O	O
indomethacin	NN	O	O
(	(	O	O
88	CD	O	O
%	NN	O	O
and	CC	O	O
97	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
after	IN	O	O
meloxicam	NN	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Closure	NNP	O	O
times	NNS	O	O
increased	VBD	O	O
significantly	RB	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
all	DT	O	O
three	CD	O	O
medications	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Increases	NNS	O	O
in	IN	O	O
closure	NN	O	O
time	NN	O	O
after	IN	O	O
administration	NN	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
between	IN	O	O
nabumetone	NN	O	O
and	CC	O	O
meloxicam	NN	O	O
(	(	O	O
24	CD	O	O
%	NN	O	O
and	CC	O	O
14	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
were	VBD	O	O
significantly	RB	O	O
larger	JJR	O	O
after	IN	O	O
indomethacin	JJ	O	O
administration	NN	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
In	IN	O	O
the	DT	O	O
maximum	JJ	O	O
registered	JJ	O	O
dosage	NN	O	O
,	,	O	O
nabumetone	JJ	O	O
inhibits	NNS	O	O
thromboxane	VBP	O	O
production	NN	O	O
much	RB	O	O
more	RBR	O	O
than	IN	O	O
meloxicam	NN	O	O
,	,	O	O
signifying	VBG	O	O
less	JJR	O	O
COX-2	JJ	O	O
selectivity	NN	O	O
of	IN	O	O
the	DT	O	O
former	JJ	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
both	DT	O	O
nabumetone	NN	O	O
and	CC	O	O
meloxicam	NN	O	O
cause	NN	O	O
only	RB	O	O
minor	JJ	O	O
impairment	NN	O	O
in	IN	O	O
platelet	NN	O	O
function	NN	O	O
in	IN	O	O
comparison	NN	O	O
with	IN	O	O
indomethacin	NN	O	O
and	CC	O	O
the	DT	O	O
difference	NN	O	O
between	IN	O	O
them	PRP	O	O
is	VBZ	O	O
not	RB	O	O
significant	JJ	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Gemfibrozil	NNP	O	O
,	,	O	O
a	DT	O	O
lipid-lowering	JJ	O	O
drug	NN	O	O
,	,	O	O
inhibited	VBN	O	O
cytokine-induced	JJ	O	O
production	NN	O	O
of	IN	O	O
NO	NNP	O	B-PRODUCT-OF
and	CC	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
inducible	JJ	O	B-enzyme
nitric-oxide	JJ	O	I-enzyme
synthase	NN	O	O
(	(	O	O
iNOS	NN	O	B-enzyme
)	)	O	O
in	IN	O	O
human	JJ	O	O
U373MG	NNP	O	O
astroglial	NN	O	O
cells	NNS	O	O
and	CC	O	O
primary	JJ	O	O
astrocytes	NNS	O	O
.	.	O	O

Similar	JJ	O	O
to	TO	O	O
gemfibrozil	VB	O	O
,	,	O	O
clofibrate	NN	O	O
,	,	O	O
another	DT	O	O
fibrate	JJ	O	O
drug	NN	O	O
,	,	O	O
also	RB	O	O
inhibited	VBD	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
iNOS	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
human	JJ	O	O
iNOS	JJ	O	O
promoter-driven	JJ	O	O
luciferase	NN	O	O
activity	NN	O	O
by	IN	O	O
gemfibrozil	NN	O	O
in	IN	O	O
cytokine-stimulated	JJ	O	O
U373MG	NNP	O	O
astroglial	JJ	O	O
cells	NNS	O	O
suggests	VBZ	O	O
that	IN	O	O
this	DT	O	O
compound	NN	O	O
inhibits	VBZ	O	O
the	DT	O	O
transcription	NN	O	O
of	IN	O	O
iNOS	NN	O	O
.	.	O	O

Since	IN	O	O
gemfibrozil	NN	O	O
is	VBZ	O	O
known	VBN	O	O
to	TO	O	O
activate	VB	O	O
peroxisome	JJ	O	O
proliferator-activated	JJ	O	O
receptor-alpha	NN	O	O
(	(	O	O
PPAR-alpha	NNP	O	O
)	)	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
PPAR-alpha	NNP	O	O
in	IN	O	O
gemfibrozil-mediated	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
iNOS	NN	O	O
.	.	O	O

Gemfibrozil	NNP	O	O
induced	VBD	O	O
peroxisome	JJ	O	O
proliferator-responsive	JJ	O	O
element	NN	O	O
(	(	O	O
PPRE	NNP	O	O
)	)	O	O
-dependent	JJ	O	O
luciferase	NN	O	O
activity	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
DeltahPPAR-alpha	NNP	O	O
,	,	O	O
the	DT	O	O
dominant-negative	JJ	O	O
mutant	NN	O	O
of	IN	O	O
human	JJ	O	O
PPAR-alpha	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
DeltahPPAR-alpha	NNP	O	O
was	VBD	O	O
unable	JJ	O	O
to	TO	O	O
abrogate	VB	O	O
gemfibrozil-mediated	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
iNOS	NN	O	O
suggesting	VBG	O	O
that	IN	O	O
gemfibrozil	JJ	O	O
inhibits	NNS	O	O
iNOS	VBP	O	O
independent	JJ	O	O
of	IN	O	O
PPAR-alpha	NNP	O	O
.	.	O	O

The	DT	O	O
human	JJ	O	O
iNOS	NN	O	O
promoter	NN	O	O
contains	VBZ	O	O
consensus	NN	O	O
sequences	NNS	O	O
for	IN	O	O
the	DT	O	O
binding	NN	O	O
of	IN	O	O
transcription	NN	O	O
factors	NNS	O	O
,	,	O	O
including	VBG	O	O
interferon-gamma	JJ	O	O
(	(	O	O
IFN-gamma	NNP	O	O
)	)	O	O
regulatory	JJ	O	O
factor-1	JJ	O	O
(	(	O	O
IRF-1	NNP	O	O
)	)	O	O
binding	VBG	O	O
to	TO	O	O
interferon-stimulated	JJ	O	O
responsive	JJ	O	O
element	NN	O	O
(	(	O	O
ISRE	NNP	O	O
)	)	O	O
,	,	O	O
signal	JJ	O	O
transducer	NN	O	O
and	CC	O	O
activator	NN	O	O
of	IN	O	O
transcription	NN	O	O
(	(	O	O
STAT	NNP	O	O
)	)	O	O
binding	VBG	O	O
to	TO	O	O
gamma-activation	NN	O	O
site	NN	O	O
(	(	O	O
GAS	NNP	O	O
)	)	O	O
,	,	O	O
nuclear	JJ	O	O
factor-kappaB	JJ	O	O
(	(	O	O
NF-kappaB	NNP	O	O
)	)	O	O
,	,	O	O
activator	JJ	O	O
protein-1	NN	O	O
(	(	O	O
AP-1	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
CCAAT/enhancer-binding	NNP	O	O
protein	NN	O	O
beta	NN	O	O
(	(	O	O
C/EBPbeta	NNP	O	O
)	)	O	O
;	:	O	O
therefore	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
gemfibrozil	NN	O	O
on	IN	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
these	DT	O	O
transcription	NN	O	O
factors	NNS	O	O
.	.	O	O

The	DT	O	O
combination	NN	O	O
of	IN	O	O
interleukin	NN	O	O
(	(	O	O
IL	NNP	O	O
)	)	O	O
-1beta	NN	O	O
and	CC	O	O
IFN-gamma	NNP	O	O
induced	VBD	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
NF-kappaB	NNP	O	O
,	,	O	O
AP-1	NNP	O	O
,	,	O	O
C/EBPbeta	NNP	O	O
,	,	O	O
and	CC	O	O
GAS	NNP	O	O
but	CC	O	O
not	RB	O	O
that	IN	O	O
of	IN	O	O
ISRE	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
IRF-1	NNP	O	O
may	MD	O	O
not	RB	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
cytokine-induced	JJ	O	O
expression	NN	O	O
of	IN	O	O
iNOS	NN	O	O
in	IN	O	O
human	JJ	O	O
astrocytes	NNS	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
gemfibrozil	JJ	O	O
strongly	RB	O	O
inhibited	VBD	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
NF-kappaB	NNP	O	O
,	,	O	O
AP-1	NNP	O	O
,	,	O	O
and	CC	O	O
C/EBPbeta	NNP	O	O
but	CC	O	O
not	RB	O	O
that	IN	O	O
of	IN	O	O
GAS	NNP	O	O
in	IN	O	O
cytokine-stimulated	JJ	O	O
astroglial	JJ	O	O
cells	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
gemfibrozil	NN	O	O
inhibits	VBZ	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
iNOS	NN	O	O
probably	RB	O	O
by	IN	O	O
inhibiting	VBG	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
NF-kappaB	NNP	O	O
,	,	O	O
AP-1	NNP	O	O
,	,	O	O
and	CC	O	O
C/EBPbeta	NNP	O	O
and	CC	O	O
that	IN	O	O
gemfibrozil	NN	O	O
,	,	O	O
a	DT	O	O
prescribed	JJ	O	O
drug	NN	O	O
for	IN	O	O
humans	NNS	O	O
,	,	O	O
may	MD	O	O
further	RB	O	O
find	VB	O	O
its	PRP$	O	O
therapeutic	JJ	O	O
use	NN	O	O
in	IN	O	O
neuroinflammatory	JJ	O	O
diseases	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Neuroinflammation	NN	O	O
and	CC	O	O
oxidative	JJ	O	O
stress	NN	O	O
are	VBP	O	O
believed	VBN	O	O
to	TO	O	O
be	VB	O	O
contributing	VBG	O	O
factors	NNS	O	O
to	TO	O	O
neurodegeneration	NN	O	O
in	IN	O	O
normal	JJ	O	O
aging	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
age-related	JJ	O	O
neurological	JJ	O	O
disorders	NNS	O	O
.	.	O	O

Reactive	JJ	O	O
microglia	NNS	O	O
are	VBP	O	O
found	VBN	O	O
in	IN	O	O
increased	JJ	O	O
numbers	NNS	O	O
in	IN	O	O
aging	VBG	O	O
brain	NN	O	O
and	CC	O	O
are	VBP	O	O
prominently	RB	O	O
associated	VBN	O	O
with	IN	O	O
lesions	NNS	O	O
in	IN	O	O
such	JJ	O	O
age-related	JJ	O	O
degenerative	JJ	O	O
conditions	NNS	O	O
as	IN	O	O
Alzheimer	NNP	O	O
's	POS	O	O
disease	NN	O	O
(	(	O	O
AD	NNP	O	O
)	)	O	O
,	,	O	O
Parkinson	NNP	O	O
's	POS	O	O
disease	NN	O	O
(	(	O	O
PD	NNP	O	O
)	)	O	O
and	CC	O	O
amyotrophic	JJ	O	O
lateral	JJ	O	O
sclerosis	NN	O	O
(	(	O	O
ALS	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
vitro	NN	O	O
,	,	O	O
stimulated	VBN	O	O
microglia	NNS	O	O
or	CC	O	O
microglial-like	JJ	O	O
cells	NNS	O	O
secrete	JJ	O	O
neurotoxic	JJ	O	O
materials	NNS	O	O
and	CC	O	O
are	VBP	O	O
generators	NNS	O	O
of	IN	O	O
free	JJ	O	O
radicals	NNS	O	O
through	IN	O	O
their	PRP$	O	O
respiratory	NN	O	O
burst	NN	O	O
system	NN	O	O
.	.	O	O

Agents	NNS	O	O
that	WDT	O	O
suppress	VBP	O	O
microglial	JJ	O	O
activation	NN	O	O
are	VBP	O	O
therefore	RB	O	O
candidates	NNS	O	O
for	IN	O	O
neuroprotection	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
developed	VBN	O	O
quantitative	JJ	O	O
in	IN	O	O
vitro	NN	O	O
assays	NNS	O	O
for	IN	O	O
measuring	VBG	O	O
neurotoxicity	NN	O	O
of	IN	O	O
microglia	NN	O	O
or	CC	O	O
other	JJ	O	O
mononuclear	JJ	O	O
phagocytes	NNS	O	O
.	.	O	O

Neuronal	JJ	O	O
like	IN	O	O
SH-SY5Y	NNP	O	O
cells	NNS	O	O
are	VBP	O	O
cultured	VBN	O	O
in	IN	O	O
supernatants	NNS	O	O
from	IN	O	O
activated	JJ	O	O
cells	NNS	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
monocytic	JJ	O	O
THP-1	NNP	O	O
line	NN	O	O
and	CC	O	O
their	PRP$	O	O
survival	NN	O	O
is	VBZ	O	O
followed	VBN	O	O
.	.	O	O

Respiratory	NNP	O	O
burst	NN	O	O
is	VBZ	O	O
directly	RB	O	O
measured	VBN	O	O
on	IN	O	O
the	DT	O	O
activated	JJ	O	O
cells	NNS	O	O
.	.	O	O

We	PRP	O	O
tested	VBD	O	O
inhibitors	NNS	O	O
of	IN	O	O
the	DT	O	O
cyclooxygenase	NN	O	O
(	(	O	O
COX	NNP	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
5-lipoxygenase	JJ	O	O
(	(	O	O
5-LOX	JJ	O	O
)	)	O	O
pathways	VBZ	O	O
as	IN	O	O
possible	JJ	O	O
neuroprotective	JJ	O	O
agents	NNS	O	O
.	.	O	O

The	DT	O	O
COX	NNP	O	B-enzyme
pathway	NN	O	O
generates	VBZ	O	O
inflammatory	JJ	O	O
prostaglandins	NNS	O	B-PRODUCT-OF
,	,	O	O
while	IN	O	O
the	DT	O	O
5-LOX	JJ	O	B-enzyme
pathway	NN	O	O
generates	VBZ	O	O
inflammatory	JJ	O	O
leukotrienes	NNS	O	B-PRODUCT-OF
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
inhibitors	NNS	O	O
of	IN	O	O
both	DT	O	O
these	DT	O	O
pathways	NNS	O	O
suppressed	VBD	O	O
neurotoxicity	NN	O	O
in	IN	O	O
a	DT	O	O
dose-dependent	JJ	O	O
fashion	NN	O	O
.	.	O	O

They	PRP	O	O
included	VBD	O	O
the	DT	O	O
COX-1	NNP	O	O
inhibitor	NN	O	O
indomethacin	NN	O	O
;	:	O	O
the	DT	O	O
COX-2	NNP	O	O
inhibitor	NN	O	O
NS-398	NNP	O	O
;	:	O	O
the	DT	O	O
mixed	JJ	O	O
COX-1/COX-2	NNP	O	O
inhibitor	NN	O	O
ibuprofen	NN	O	O
;	:	O	O
the	DT	O	O
nitric	JJ	O	O
oxide	NN	O	O
(	(	O	O
NO	NNP	O	O
)	)	O	O
derivatives	NNS	O	O
of	IN	O	O
indomethacin	NN	O	O
,	,	O	O
ibuprofen	NN	O	O
and	CC	O	O
flurbiprofen	NN	O	O
;	:	O	O
the	DT	O	O
5-LOX	JJ	O	O
inhibitor	NN	O	O
REV	NNP	O	O
5901	CD	O	O
;	:	O	O
and	CC	O	O
the	DT	O	O
5-LOX	JJ	O	O
activating	NN	O	O
protein	NN	O	O
(	(	O	O
FLAP	NNP	O	O
)	)	O	O
inhibitor	NN	O	O
MK-886	NNP	O	O
.	.	O	O

The	DT	O	O
FLAP	NNP	O	O
inhibitor	NN	O	O
also	RB	O	O
reduced	VBD	O	O
respiratory	JJ	O	O
burst	NN	O	O
activity	NN	O	O
in	IN	O	O
a	DT	O	O
more	RBR	O	O
potent	JJ	O	O
manner	NN	O	O
than	IN	O	O
indomethacin	NN	O	O
.	.	O	O

Combinations	NNS	O	O
of	IN	O	O
COX	NNP	O	O
and	CC	O	O
5-LOX	JJ	O	O
inhibitors	NNS	O	O
were	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
single	JJ	O	O
inhibitors	NNS	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
suggest	NN	O	O
that	IN	O	O
both	DT	O	O
COX	NNP	O	O
inhibitors	NNS	O	O
and	CC	O	O
5-LOX	JJ	O	O
inhibitors	NNS	O	O
may	MD	O	O
be	VB	O	O
neuroprotective	JJ	O	O
in	IN	O	O
vivo	NN	O	O
by	IN	O	O
suppressing	VBG	O	O
toxic	JJ	O	O
actions	NNS	O	O
of	IN	O	O
microglia/macrophages	NNS	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
combinations	NNS	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
might	MD	O	O
have	VB	O	O
greater	JJR	O	O
therapeutic	JJ	O	O
potential	NN	O	O
than	IN	O	O
single	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
either	DT	O	O
class	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Salix	NNP	O	O
extracts	NNS	O	O
are	VBP	O	O
in	IN	O	O
current	JJ	O	O
use	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pain	NN	O	O
and	CC	O	O
inflammation	NN	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
obtain	VB	O	O
an	DT	O	O
insight	NN	O	O
into	IN	O	O
the	DT	O	O
mechanism	NN	O	O
(	(	O	O
s	JJ	O	O
)	)	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
the	DT	O	O
ethanolic	JJ	O	O
Salix	NNP	O	O
extract	NN	O	O
1520L	CD	O	O
--	:	O	O
which	WDT	O	O
is	VBZ	O	O
essentially	RB	O	O
similar	JJ	O	O
to	TO	O	O
an	DT	O	O
extract	NN	O	O
for	IN	O	O
which	WDT	O	O
clinical	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
demonstrated	VBN	O	O
analgesic	JJ	O	O
effectiveness	NN	O	O
--	:	O	O
its	PRP$	O	O
effects	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
an	DT	O	O
established	VBN	O	O
in	IN	O	O
vitro	NNS	O	O
assay	VBP	O	O
test	NN	O	O
system	NN	O	O
using	VBG	O	O
primary	JJ	O	O
human	JJ	O	O
monocytes	NNS	O	O
.	.	O	O

The	DT	O	O
IC50-values	NNP	O	O
obtained	VBD	O	O
for	IN	O	O
the	DT	O	O
inhibition	NN	O	O
of	IN	O	O
lipopolysaccharide	NN	O	O
(	(	O	O
LPS	NNP	O	O
)	)	O	O
-induced	VBD	O	O
release	NN	O	O
of	IN	O	O
prostaglandin	NN	O	O
E2	NNP	O	O
(	(	O	O
PGE2	NNP	O	O
)	)	O	O
reflecting	VBG	O	O
cyclooxygenase	NN	O	B-enzyme
(	(	O	I-enzyme
COX	NNP	O	I-enzyme
)	)	O	I-enzyme
-2-mediated	VBD	O	O
PGE2	NNP	O	B-PRODUCT-OF
release	NN	O	O
were	VBD	O	O
47	CD	O	O
microg/ml	NNS	O	O
and	CC	O	O
0.6	CD	O	O
microg/ml	NN	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
Salix	NNP	O	O
extract	NN	O	O
1520L	CD	O	O
and	CC	O	O
rofecoxib-like	JJ	O	O
research	NN	O	O
compound	NN	O	O
L745337	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
COX-1	NNP	O	O
and	CC	O	O
COX-2	NNP	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
Salix	NNP	O	O
extract	NN	O	O
inhibited	VBD	O	O
the	DT	O	O
LPS-induced	JJ	O	O
release	NN	O	O
of	IN	O	O
tumor	NN	O	O
necrosis	NN	O	O
factor-alpha	JJ	O	O
,	,	O	O
interleukin-1beta	JJ	O	O
and	CC	O	O
interleukin-6	JJ	O	O
with	IN	O	O
IC50-values	NNP	O	O
of	IN	O	O
180.0	CD	O	O
,	,	O	O
33.0	CD	O	O
and	CC	O	O
86.0	CD	O	O
microg/ml	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Both	DT	O	O
,	,	O	O
salicin	NN	O	O
and	CC	O	O
salicylate	NN	O	O
,	,	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
parameters	NNS	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
Salix	NNP	O	O
extract	VBD	O	O
1520L	CD	O	O
inhibits	NNS	O	O
COX-2-mediated	JJ	O	O
PGE2	NNP	O	B-PRODUCT-OF
release	NN	O	O
through	IN	O	O
compounds	VBZ	O	O
other	JJ	O	O
than	IN	O	O
salicin	NNS	O	O
or	CC	O	O
salicylate	NN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
further	RBR	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
proprietary	JJ	O	O
Salix	NNP	O	O
extract	NN	O	O
is	VBZ	O	O
a	DT	O	O
weak	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
proinflammatory	JJ	O	O
cytokines	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

In	IN	O	O
eukaryotes	NNS	O	O
,	,	O	O
L-carnitine	NNP	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
energy	NN	O	O
metabolism	NN	O	O
by	IN	O	O
facilitating	VBG	O	O
beta-oxidation	NN	O	O
of	IN	O	O
fatty	JJ	O	O
acids	NNS	O	O
.	.	O	O

Carnitine	NN	O	B-enzyme
acetyltransferases	NNS	O	I-enzyme
(	(	O	O
CrAT	NNP	O	B-enzyme
)	)	O	O
catalyze	VBP	O	O
the	DT	O	O
reversible	JJ	O	O
conversion	NN	O	O
of	IN	O	O
acetyl-CoA	JJ	O	B-SUBSTRATE
and	CC	O	O
carnitine	NN	O	B-SUBSTRATE
to	TO	O	O
acetylcarnitine	VB	O	B-PRODUCT-OF
and	CC	O	O
free	JJ	O	O
CoA	NNP	O	O
.	.	O	O

To	TO	O	O
redesign	VB	O	O
the	DT	O	O
specificity	NN	O	O
of	IN	O	O
rat	NN	O	O
CrAT	NNP	O	O
toward	IN	O	O
its	PRP$	O	O
substrates	NNS	O	O
,	,	O	O
we	PRP	O	O
mutated	VBD	O	O
Met564	NNP	O	O
.	.	O	O

The	DT	O	O
M564G	NNP	O	B-enzyme
mutated	VBD	O	O
CrAT	NNP	O	B-enzyme
showed	VBD	O	O
higher	JJR	O	O
activity	NN	O	O
toward	IN	O	O
longer	JJR	O	O
chain	NN	O	O
acyl-CoAs	JJ	O	B-SUBSTRATE
:	:	O	O
activity	NN	O	O
toward	IN	O	O
myristoyl-CoA	NN	O	B-SUBSTRATE
was	VBD	O	O
1250-fold	JJ	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
wild-type	JJ	O	O
CrAT	NNP	O	B-enzyme
,	,	O	O
and	CC	O	O
lower	JJR	O	O
activity	NN	O	O
toward	IN	O	O
its	PRP$	O	O
natural	JJ	O	O
substrate	NN	O	O
,	,	O	O
acetyl-CoA	NN	O	B-SUBSTRATE
.	.	O	O

Kinetic	JJ	O	O
constants	NNS	O	O
of	IN	O	O
the	DT	O	O
mutant	JJ	O	O
CrAT	NNP	O	B-enzyme
showed	VBD	O	O
modification	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
longer	JJR	O	O
acyl-CoAs	NN	O	B-SUBSTRATE
as	IN	O	O
substrates	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
reverse	NN	O	O
case	NN	O	O
,	,	O	O
mutation	NN	O	O
of	IN	O	O
the	DT	O	O
orthologous	JJ	O	O
glycine	NN	O	O
(	(	O	O
Gly553	NNP	O	O
)	)	O	O
to	TO	O	O
methionine	VB	O	O
in	IN	O	O
carnitine	JJ	O	B-enzyme
octanoyltransferase	NN	O	I-enzyme
(	(	O	O
COT	NNP	O	B-enzyme
)	)	O	O
decreased	VBD	O	O
activity	NN	O	O
toward	IN	O	O
its	PRP$	O	O
natural	JJ	O	O
substrates	NNS	O	O
,	,	O	O
medium-	JJ	O	O
and	CC	O	O
long-chain	JJ	O	O
acyl-CoAs	NN	O	B-SUBSTRATE
,	,	O	O
and	CC	O	O
increased	VBD	O	O
activity	NN	O	O
toward	IN	O	O
short-chain	JJ	O	O
acyl-CoAs	NN	O	B-SUBSTRATE
.	.	O	O

Another	DT	O	O
CrAT	NNP	O	O
mutant	NN	O	O
,	,	O	O
M564A	NNP	O	O
,	,	O	O
was	VBD	O	O
prepared	VBN	O	O
and	CC	O	O
tested	VBN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
way	NN	O	O
,	,	O	O
with	IN	O	O
similar	JJ	O	O
results	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
Met564	NNP	O	O
blocks	VBZ	O	O
the	DT	O	O
entry	NN	O	O
of	IN	O	O
medium-	JJ	O	O
and	CC	O	O
long-chain	JJ	O	O
acyl-CoAs	NN	O	B-SUBSTRATE
to	TO	O	O
the	DT	O	O
catalytic	JJ	O	O
site	NN	O	O
of	IN	O	O
CrAT	NNP	O	B-enzyme
.	.	O	O

Three-dimensional	JJ	O	O
models	NNS	O	O
of	IN	O	O
wild-type	JJ	O	O
and	CC	O	O
mutated	JJ	O	O
CrAT	NNP	O	O
and	CC	O	O
COT	NNP	O	O
support	NN	O	O
this	DT	O	O
hypothesis	NN	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
that	IN	O	O
a	DT	O	O
single	JJ	O	O
amino	NN	O	O
acid	NN	O	O
is	VBZ	O	O
able	JJ	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
substrate	JJ	O	O
specificity	NN	O	O
of	IN	O	O
CrAT	NNP	O	O
and	CC	O	O
COT	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Megalin	NNP	O	O
,	,	O	O
a	DT	O	O
family	NN	O	O
of	IN	O	O
endocytic	JJ	O	B-enzyme
receptors	NNS	O	I-enzyme
related	VBN	O	O
to	TO	O	O
the	DT	O	O
low-density	NN	O	B-enzyme
lipoprotein	NN	O	I-enzyme
(	(	O	O
LDL	NNP	O	O
)	)	O	O
receptor	NN	O	O
,	,	O	O
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
pathway	NN	O	O
for	IN	O	O
proximal	JJ	O	O
tubular	JJ	O	O
aminoglycoside	NN	O	B-SUBSTRATE
accumulation	NN	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
reported	VBD	O	O
that	IN	O	O
aminoglycoside	IN	O	O
antibiotics	NNS	O	O
reduce	VB	O	O
SGLT1-dependent	NNP	O	O
glucose	JJ	O	O
transport	NN	O	O
in	IN	O	O
pig	NN	O	O
proximal	JJ	O	O
tubular	JJ	O	O
epithelial	JJ	O	O
LLC-PK1	NNP	O	O
cells	NNS	O	O
in	IN	O	O
parallel	NN	O	O
with	IN	O	O
the	DT	O	O
order	NN	O	O
of	IN	O	O
their	PRP$	O	O
nephrotoxicity	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
using	VBG	O	O
a	DT	O	O
model	NN	O	O
of	IN	O	O
gentamicin	JJ	O	O
C	NNP	O	O
(	(	O	O
GMC	NNP	O	O
)	)	O	O
-induced	VBD	O	O
reduction	NN	O	O
in	IN	O	O
SGLT1	NNP	O	O
activity	NN	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
whether	IN	O	O
ligands	NNS	O	O
for	IN	O	O
megalin	NN	O	O
protect	JJ	O	O
LLC-PK1	NNP	O	O
cells	NNS	O	O
from	IN	O	O
the	DT	O	O
GMC-induced	NNP	O	O
reduction	NN	O	O
in	IN	O	O
SGLT1	NNP	O	O
activity	NN	O	O
.	.	O	O

We	PRP	O	O
employed	VBD	O	O
apolipoprotein	RP	O	O
E3	NNP	O	O
(	(	O	O
apoE3	NN	O	O
)	)	O	O
and	CC	O	O
lactoferrin	$	O	O
as	IN	O	O
ligands	NNS	O	O
for	IN	O	O
megalin	NN	O	O
.	.	O	O

Then	RB	O	O
the	DT	O	O
cells	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
various	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
apoE3	NN	O	O
,	,	O	O
lactoferrin	NN	O	O
and	CC	O	O
bovine	NN	O	O
serum	NN	O	O
albumin	NN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
100	CD	O	O
microg/ml	NN	O	O
of	IN	O	O
GMC	NNP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
SGLT1-dependent	JJ	O	O
methyl	NN	O	B-SUBSTRATE
alpha-D-glucopyranoside	NN	O	I-SUBSTRATE
(	(	O	O
AMG	NNP	O	B-SUBSTRATE
)	)	O	O
uptake	NN	O	O
and	CC	O	O
levels	NNS	O	O
of	IN	O	O
SGLT1	NNP	O	O
expression	NN	O	O
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
result	NN	O	O
,	,	O	O
we	PRP	O	O
demonstrated	VBD	O	O
that	IN	O	O
the	DT	O	O
apoE3	NN	O	O
significantly	RB	O	O
protects	VBZ	O	O
these	DT	O	O
cells	NNS	O	O
from	IN	O	O
GMC-induced	NNP	O	O
reduction	NN	O	O
in	IN	O	O
AMG	NNP	O	O
uptake	NN	O	O
,	,	O	O
but	CC	O	O
neither	DT	O	O
lactoferrin	JJ	O	O
nor	CC	O	O
albumin	JJ	O	O
does	VBZ	O	O
.	.	O	O

In	IN	O	O
accord	NN	O	O
with	IN	O	O
a	DT	O	O
rise	NN	O	O
in	IN	O	O
AMG	NNP	O	O
uptake	JJ	O	O
activity	NN	O	O
,	,	O	O
the	DT	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
levels	NNS	O	O
of	IN	O	O
SGLT1	NNP	O	O
were	VBD	O	O
apparently	RB	O	O
up-regulated	JJ	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
apoE3	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
the	DT	O	O
uptake	NN	O	O
of	IN	O	O
[	$	O	O
3H	CD	O	O
]	NNP	O	O
gentamicin	NN	O	O
is	VBZ	O	O
decreased	VBN	O	O
by	IN	O	O
apoE3	NN	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
apoE3	NN	O	O
showed	VBD	O	O
obvious	JJ	O	O
protection	NN	O	O
against	IN	O	O
the	DT	O	O
GMC-dependent	JJ	O	O
N-acetyl-beta-D-glucosamidase	NNP	O	O
(	(	O	O
NAG	NNP	O	O
)	)	O	O
release	NN	O	O
from	IN	O	O
LLC-PK1	NNP	O	O
cells	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
apoE3	NN	O	O
could	MD	O	O
be	VB	O	O
a	DT	O	O
valuable	JJ	O	O
tool	NN	O	O
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
aminoglycoside	JJ	O	O
nephrotoxicity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Rifampicin	NNP	O	O
,	,	O	O
an	DT	O	O
important	JJ	O	O
drug	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
tuberculosis	NN	O	O
,	,	O	O
is	VBZ	O	O
used	VBN	O	O
extensively	RB	O	O
despite	IN	O	O
its	PRP$	O	O
broad	JJ	O	O
effects	NNS	O	O
on	IN	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
,	,	O	O
creating	VBG	O	O
serious	JJ	O	O
problems	NNS	O	O
.	.	O	O

The	DT	O	O
clinical	JJ	O	O
importance	NN	O	O
of	IN	O	O
such	JJ	O	O
interactions	NNS	O	O
includes	VBZ	O	O
autoinduction	NN	O	O
leading	VBG	O	O
to	TO	O	O
suboptimal	VB	O	O
or	CC	O	O
failed	VB	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
concomitantly	RB	O	O
administered	VBN	O	O
effects	NNS	O	O
of	IN	O	O
rifampicin	NN	O	B-SUBSTRATE
on	IN	O	O
other	JJ	O	O
drugs	NNS	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
their	PRP$	O	O
altered	JJ	O	O
metabolism	NN	O	O
or	CC	O	O
transportation	NN	O	O
that	WDT	O	O
are	VBP	O	O
metabolised	VBN	O	O
by	IN	O	O
cytochromes	NNS	O	B-enzyme
P450	NNP	O	I-enzyme
or	CC	O	O
transported	VBN	O	O
by	IN	O	O
p-glycoprotein	NN	O	B-enzyme
in	IN	O	O
the	DT	O	O
gastrointestinal	JJ	O	O
tract	NN	O	O
and	CC	O	O
liver	NN	O	O
.	.	O	O

This	DT	O	O
review	NN	O	O
paper	NN	O	O
summarises	VBZ	O	O
recent	JJ	O	O
findings	NNS	O	O
with	IN	O	O
emphases	NNS	O	O
on	IN	O	O
the	DT	O	O
molecular	JJ	O	O
mechanisms	NNS	O	O
used	VBN	O	O
to	TO	O	O
explain	VB	O	O
these	DT	O	O
broad	JJ	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
.	.	O	O

In	IN	O	O
general	JJ	O	O
,	,	O	O
rifampicin	NN	O	O
can	MD	O	O
act	VB	O	O
on	IN	O	O
a	DT	O	O
pattern	NN	O	O
:	:	O	O
rifampicin	NN	O	O
activates	VBZ	O	O
the	DT	O	O
nuclear	JJ	O	O
pregnane	NN	O	O
X	NNP	O	O
receptor	NN	O	O
that	IN	O	O
in	IN	O	O
turn	NN	O	O
affects	NNS	O	O
cytochromes	VBZ	O	O
P450	NNP	O	O
,	,	O	O
glucuronosyltransferases	NNS	O	O
and	CC	O	O
p-glycoprotein	JJ	O	O
activities	NNS	O	O
.	.	O	O

This	DT	O	O
pattern	NN	O	O
of	IN	O	O
action	NN	O	O
may	MD	O	O
explain	VB	O	O
many	JJ	O	O
of	IN	O	O
the	DT	O	O
rifampicin	NN	O	O
inducing	VBG	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
effects	NNS	O	O
through	IN	O	O
other	JJ	O	O
mechanisms	NNS	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
reported	VBN	O	O
and	CC	O	O
these	DT	O	O
make	VBP	O	O
any	DT	O	O
explanation	NN	O	O
of	IN	O	O
such	JJ	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
more	RBR	O	O
complex	JJ	O	O
.	.	O	O

-DOCSTART- -X- -X- O

We	PRP	O	O
demonstrated	VBD	O	O
previously	RB	O	O
that	IN	O	O
exogenous	JJ	O	O
pyruvate	NN	O	O
has	VBZ	O	O
a	DT	O	O
protective	JJ	O	O
action	NN	O	O
against	IN	O	O
cell	NN	O	O
death	NN	O	O
by	IN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
in	IN	O	O
cultured	JJ	O	O
osteoblasts	NNS	O	O
through	IN	O	O
a	DT	O	O
mechanism	NN	O	O
associated	VBN	O	O
with	IN	O	O
its	PRP$	O	O
antioxidative	JJ	O	O
property	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
evaluated	VBN	O	O
possible	JJ	O	O
participation	NN	O	O
of	IN	O	O
monocarboxylate	NN	O	B-enzyme
transporters	NNS	O	I-enzyme
(	(	O	O
MCTs	NNP	O	B-enzyme
)	)	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
bidirectional	JJ	O	O
membrane	NN	O	O
transport	NN	O	O
of	IN	O	O
pyruvate	NN	O	B-SUBSTRATE
in	IN	O	O
the	DT	O	O
cytoprotective	JJ	O	O
property	NN	O	O
in	IN	O	O
osteoblasts	NNS	O	O
.	.	O	O

Expression	NN	O	O
of	IN	O	O
the	DT	O	O
MCT2	NNP	O	O
isoform	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
cultured	JJ	O	O
rat	NN	O	O
calvarial	JJ	O	O
osteoblasts	NNS	O	O
and	CC	O	O
in	IN	O	O
osteoblasts	NNS	O	O
located	VBN	O	O
on	IN	O	O
mouse	NN	O	O
tibia	NN	O	O
at	IN	O	O
both	DT	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
levels	NNS	O	O
.	.	O	O

The	DT	O	O
accumulation	NN	O	O
of	IN	O	O
[	$	O	O
14C	CD	O	O
]	NNP	O	O
pyruvate	NN	O	O
occurred	VBD	O	O
in	IN	O	O
a	DT	O	O
temperature-	JJ	O	O
and	CC	O	O
pH-dependent	JJ	O	O
manner	NN	O	O
in	IN	O	O
osteoblasts	NNS	O	O
cultured	VBD	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
with	IN	O	O
high	JJ	O	O
sensitivity	NN	O	O
to	TO	O	O
a	DT	O	O
specific	JJ	O	O
MCT	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
whereas	JJ	O	O
pyruvate	NN	O	O
was	VBD	O	O
released	VBN	O	O
into	IN	O	O
extracellular	JJ	O	O
spaces	NNS	O	O
from	IN	O	O
cultured	JJ	O	O
osteoblasts	NNS	O	O
in	IN	O	O
a	DT	O	O
fashion	NN	O	O
sensitive	NN	O	O
to	TO	O	O
the	DT	O	O
MCT	NNP	O	O
inhibitor	NN	O	O
.	.	O	O

Transient	JJ	O	O
overexpression	NN	O	O
of	IN	O	O
the	DT	O	O
MCT2	NNP	O	O
isoform	NN	O	O
led	VBD	O	O
to	TO	O	O
reduced	VB	O	O
vulnerability	NN	O	O
to	TO	O	O
the	DT	O	O
cytotoxicity	NN	O	O
of	IN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
with	IN	O	O
an	DT	O	O
increased	JJ	O	O
activity	NN	O	O
of	IN	O	O
[	$	O	O
14C	CD	O	O
]	NNP	O	O
pyruvate	NN	O	O
accumulation	NN	O	O
in	IN	O	O
murine	JJ	O	O
osteoblastic	JJ	O	O
MC3T3-E1	NNP	O	O
cells	NNS	O	O
.	.	O	O

Ovariectomy	NNP	O	O
significantly	RB	O	O
decreased	VBD	O	O
the	DT	O	O
content	NN	O	O
of	IN	O	O
pyruvate	NN	O	O
in	IN	O	O
femoral	JJ	O	O
bone	NN	O	O
marrows	NNS	O	O
in	IN	O	O
mice	NN	O	O
in	IN	O	O
vivo	NN	O	O
,	,	O	O
whereas	JJ	O	O
daily	JJ	O	O
i.p	NN	O	O
.	.	O	O

administration	NN	O	O
of	IN	O	O
pyruvate	NN	O	O
at	IN	O	O
0.25	CD	O	O
g/kg	NNS	O	O
significantly	RB	O	O
prevented	VBD	O	O
alterations	NNS	O	O
of	IN	O	O
several	JJ	O	O
histomorphometric	JJ	O	O
parameters	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
cancellous	JJ	O	O
bone	NN	O	O
loss	NN	O	O
in	IN	O	O
femurs	NNS	O	O
by	IN	O	O
ovariectomy	NN	O	O
on	IN	O	O
28	CD	O	O
days	NNS	O	O
after	IN	O	O
the	DT	O	O
operation	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
MCTs	NNP	O	O
may	MD	O	O
be	VB	O	O
functionally	RB	O	O
expressed	VBN	O	O
by	IN	O	O
osteoblasts	NNS	O	O
to	TO	O	O
play	VB	O	O
a	DT	O	O
pivotal	JJ	O	O
role	NN	O	O
in	IN	O	O
mechanisms	NNS	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
cytoprotective	JJ	O	O
property	NN	O	O
of	IN	O	O
pyruvate	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Choline	NNP	O	B-enzyme
dehydrogenase	NN	O	I-enzyme
(	(	O	O
CHDH	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
betaine-homocysteine	JJ	O	B-enzyme
methyltransferase	NN	O	I-enzyme
(	(	O	O
BHMT	NNP	O	B-enzyme
)	)	O	O
are	VBP	O	O
2	CD	O	O
enzymes	NNS	O	O
involved	VBN	O	O
in	IN	O	O
choline	JJ	O	B-SUBSTRATE
oxidation	NN	O	O
.	.	O	O

BHMT	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
at	IN	O	O
high	JJ	O	O
levels	NNS	O	O
in	IN	O	O
rat	NN	O	O
liver	NN	O	O
and	CC	O	O
its	PRP$	O	O
expression	NN	O	O
is	VBZ	O	O
regulated	VBN	O	O
by	IN	O	O
dietary	JJ	O	O
Met	NNP	O	O
and	CC	O	O
choline	NN	O	O
.	.	O	O

BHMT	NNP	O	O
is	VBZ	O	O
also	RB	O	O
found	VBN	O	O
in	IN	O	O
rat	NN	O	O
kidney	NN	O	O
,	,	O	O
albeit	NN	O	O
in	IN	O	O
substantially	RB	O	O
lower	JJR	O	O
amounts	NNS	O	O
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
kidney	NN	O	O
BHMT	NNP	O	O
expression	NN	O	O
is	VBZ	O	O
regulated	VBN	O	O
by	IN	O	O
dietary	JJ	O	O
Met	NNP	O	O
or	CC	O	O
choline	NN	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
CHDH	NNP	O	O
activity	NN	O	O
is	VBZ	O	O
highest	JJS	O	O
in	IN	O	O
the	DT	O	O
liver	NN	O	O
and	CC	O	O
kidney	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
its	PRP$	O	O
expression	NN	O	O
by	IN	O	O
diet	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
thoroughly	RB	O	O
investigated	VBN	O	O
.	.	O	O

Sprague	NNP	O	O
Dawley	NNP	O	O
rats	NNS	O	O
(	(	O	O
approximately	RB	O	O
50	CD	O	O
g	NNS	O	O
)	)	O	O
were	VBD	O	O
fed	VBN	O	O
,	,	O	O
for	IN	O	O
9	CD	O	O
d	NN	O	O
in	IN	O	O
2	CD	O	O
x	JJ	O	O
3	CD	O	O
factorial	JJ	O	O
design	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
8	CD	O	O
)	)	O	O
,	,	O	O
an	DT	O	O
l-amino	JJ	O	O
acid-defined	JJ	O	O
diet	JJ	O	O
varying	NN	O	O
in	IN	O	O
l-Met	JJ	O	O
(	(	O	O
0.125	CD	O	O
,	,	O	O
0.3	CD	O	O
,	,	O	O
or	CC	O	O
0.8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
choline	NN	O	O
(	(	O	O
0	CD	O	O
or	CC	O	O
25	CD	O	O
mmol/kg	NNS	O	O
diet	JJ	O	O
)	)	O	O
.	.	O	O

Liver	NNP	O	O
and	CC	O	O
kidney	VB	O	O
BHMT	NNP	O	O
and	CC	O	O
CHDH	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
enzymatic	JJ	O	O
,	,	O	O
Western	JJ	O	O
blot	NN	O	O
,	,	O	O
and	CC	O	O
real-time	JJ	O	O
PCR	NNP	O	O
analyses	NNS	O	O
.	.	O	O

Liver	NN	O	O
samples	NNS	O	O
were	VBD	O	O
also	RB	O	O
fixed	VBN	O	O
for	IN	O	O
histological	JJ	O	O
analysis	NN	O	O
.	.	O	O

Liver	NNP	O	O
BHMT	NNP	O	O
activity	NN	O	O
was	VBD	O	O
1.3-fold	JJ	O	O
higher	JJR	O	O
in	IN	O	O
rats	NNS	O	O
fed	VBP	O	O
the	DT	O	O
Met	NNP	O	O
deficient	NN	O	O
diet	NN	O	O
containing	VBG	O	O
choline	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
reflected	VBN	O	O
in	IN	O	O
corresponding	VBG	O	O
increases	NNS	O	O
in	IN	O	O
mRNA	NN	O	O
content	NN	O	O
and	CC	O	O
immunodetectable	JJ	O	O
protein	NN	O	O
.	.	O	O

Independent	NN	O	O
of	IN	O	O
dietary	JJ	O	O
choline	NN	O	O
,	,	O	O
supplemental	JJ	O	O
Met	NNP	O	O
increased	VBD	O	O
hepatic	JJ	O	O
BHMT	NNP	O	O
activity	NN	O	O
approximately	RB	O	O
30	CD	O	O
%	NN	O	O
.	.	O	O

Kidney	NNP	O	O
BHMT	NNP	O	O
and	CC	O	O
liver	RB	O	O
CHDH	NNP	O	O
expression	NN	O	O
were	VBD	O	O
refractory	JJ	O	O
to	TO	O	O
these	DT	O	O
diets	NNS	O	O
.	.	O	O

Some	DT	O	O
degree	NN	O	O
of	IN	O	O
fatty	JJ	O	O
liver	NN	O	O
developed	VBN	O	O
in	IN	O	O
all	DT	O	O
rats	NNS	O	O
fed	VBD	O	O
a	DT	O	O
choline-devoid	JJ	O	O
diet	NN	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
supplemental	JJ	O	O
Met	NNP	O	O
can	MD	O	O
not	RB	O	O
completely	RB	O	O
compensate	VB	O	O
for	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
dietary	JJ	O	O
choline	NN	O	O
in	IN	O	O
growing	VBG	O	O
rats	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Heterocyclic	NNP	O	O
and	CC	O	O
aromatic	JJ	O	O
amine	NN	O	O
carcinogens	NNS	O	O
are	VBP	O	O
thought	VBN	O	O
to	TO	O	O
lead	VB	O	O
to	TO	O	O
tumor	VB	O	O
initiation	NN	O	O
via	IN	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
DNA	NNP	O	O
adducts	NNS	O	O
,	,	O	O
and	CC	O	O
bioactivation	NN	O	O
to	TO	O	O
arylhydroxylamine	VB	O	O
metabolites	NNS	O	O
is	VBZ	O	O
necessary	JJ	O	O
for	IN	O	O
reactivity	NN	O	O
with	IN	O	O
DNA	NNP	O	O
.	.	O	O

Carcinogenic	NNP	O	O
arylhydroxylamine	NN	O	O
metabolites	NNS	O	O
are	VBP	O	O
cleared	VBN	O	O
by	IN	O	O
a	DT	O	O
microsomal	JJ	O	O
,	,	O	O
NADH-dependent	JJ	O	O
,	,	O	O
oxygen-insensitive	JJ	O	O
reduction	NN	O	O
pathway	NN	O	O
in	IN	O	O
humans	NNS	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
source	NN	O	O
of	IN	O	O
interindividual	JJ	O	O
variability	NN	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
aromatic	JJ	O	O
amine	NN	O	O
carcinogens	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
characterize	VB	O	O
the	DT	O	O
identity	NN	O	O
of	IN	O	O
this	DT	O	O
reduction	NN	O	O
pathway	NN	O	O
in	IN	O	O
human	JJ	O	O
liver	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
our	PRP$	O	O
findings	NNS	O	O
with	IN	O	O
structurally	RB	O	O
similar	JJ	O	O
arylhydroxylamine	NN	O	O
metabolites	NNS	O	O
of	IN	O	O
therapeutic	JJ	O	O
drugs	NNS	O	O
,	,	O	O
we	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
the	DT	O	O
reductive	JJ	O	O
detoxification	NN	O	O
of	IN	O	O
arylhydroxylamine	NN	O	B-SUBSTRATE
carcinogens	NNS	O	O
was	VBD	O	O
catalyzed	VBN	O	O
by	IN	O	O
NADH	NNP	O	B-enzyme
cytochrome	NN	O	I-enzyme
b5	NN	O	O
reductase	NN	O	O
(	(	O	O
b5R	NN	O	B-enzyme
)	)	O	O
and	CC	O	O
cytochrome	JJ	O	B-enzyme
b5	NN	O	I-enzyme
(	(	O	O
cyt	JJ	O	B-enzyme
b5	NN	O	I-enzyme
)	)	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
reduction	NN	O	O
of	IN	O	O
the	DT	O	O
carcinogenic	JJ	O	O
hydroxylamines	NNS	O	B-SUBSTRATE
of	IN	O	O
the	DT	O	O
aromatic	JJ	O	B-SUBSTRATE
amine	NN	O	I-SUBSTRATE
4-aminobiphenyl	JJ	O	B-SUBSTRATE
(	(	O	O
4-ABP	JJ	O	B-SUBSTRATE
;	:	O	O
found	VBN	O	O
in	IN	O	O
cigarette	NN	O	O
smoke	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
heterocyclic	JJ	O	B-SUBSTRATE
amine	JJ	O	I-SUBSTRATE
2-amino-1-methyl-6-phenylimidazo	JJ	O	B-SUBSTRATE
[	JJ	O	I-SUBSTRATE
4,5-b	JJ	O	I-SUBSTRATE
]	NN	O	I-SUBSTRATE
pyridine	NN	O	O
(	(	O	O
PhIP	NNP	O	B-SUBSTRATE
;	:	O	O
found	VBN	O	O
in	IN	O	O
grilled	JJ	O	O
meats	NNS	O	O
)	)	O	O
was	VBD	O	O
indeed	RB	O	O
catalyzed	VBN	O	O
by	IN	O	O
a	DT	O	O
purified	JJ	O	O
system	NN	O	O
containing	VBG	O	O
only	RB	O	O
human	JJ	O	B-enzyme
b5R	NN	O	I-enzyme
and	CC	O	O
cyt	NN	O	B-enzyme
b5	NN	O	I-enzyme
.	.	O	O

Specific	JJ	O	O
activities	NNS	O	O
were	VBD	O	O
56-346-fold	JJ	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
purified	JJ	O	O
system	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
human	JJ	O	O
liver	NN	O	O
microsomes	NNS	O	O
(	(	O	O
HLM	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
similar	JJ	O	O
Michaelis-Menten	JJ	O	O
constants	NNS	O	O
(	(	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
values	NNS	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
systems	NNS	O	O
.	.	O	O

The	DT	O	O
stoichiometry	NN	O	O
for	IN	O	O
b5R	NN	O	O
and	CC	O	O
cyt	NN	O	O
b5	NN	O	O
that	WDT	O	O
yielded	VBD	O	O
the	DT	O	O
highest	JJS	O	O
activity	NN	O	O
in	IN	O	O
the	DT	O	O
purified	JJ	O	O
system	NN	O	O
was	VBD	O	O
also	RB	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
found	VBN	O	O
in	IN	O	O
native	JJ	O	O
HLM	NNP	O	O
(	(	O	O
approximately	RB	O	O
1:8	CD	O	O
to	TO	O	O
1:10	CD	O	O
)	)	O	O
.	.	O	O

Polyclonal	NNP	O	O
antisera	NN	O	O
to	TO	O	O
either	DT	O	O
b5R	NN	O	B-enzyme
or	CC	O	O
cyt	NN	O	B-enzyme
b5	VBP	O	I-enzyme
significantly	RB	O	O
inhibited	VBN	O	O
N-hydroxy-4-aminobiphenyl	NNP	O	B-SUBSTRATE
(	(	O	O
NHOH-4-ABP	NNP	O	B-SUBSTRATE
)	)	O	O
reduction	NN	O	O
by	IN	O	O
95	CD	O	O
and	CC	O	O
89	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
immunoreactive	JJ	O	O
cyt	NN	O	O
b5	NN	O	O
protein	NN	O	O
content	NN	O	O
in	IN	O	O
individual	JJ	O	O
HLM	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
correlated	VBN	O	O
with	IN	O	O
individual	JJ	O	O
reduction	NN	O	O
of	IN	O	O
both	DT	O	O
NHOH-4-ABP	NNP	O	O
and	CC	O	O
N-hydroxy-PhIP	NNP	O	O
(	(	O	O
NHOH-PhIP	NNP	O	O
)	)	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
titration	NN	O	O
of	IN	O	O
HLM	NNP	O	O
into	IN	O	O
the	DT	O	O
purified	JJ	O	O
b5R/cyt	NN	O	O
b5	NN	O	O
system	NN	O	O
did	VBD	O	O
not	RB	O	O
enhance	VB	O	O
the	DT	O	O
efficiency	NN	O	O
of	IN	O	O
reduction	NN	O	O
activity	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
b5R	NN	O	O
and	CC	O	O
cyt	NN	O	O
b5	NN	O	O
are	VBP	O	O
together	RB	O	O
solely	RB	O	O
capable	JJ	O	O
of	IN	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
arylhydroxylamine	NN	O	O
carcinogens	NNS	O	O
,	,	O	O
and	CC	O	O
we	PRP	O	O
further	VBP	O	O
hypothesize	VB	O	O
that	IN	O	O
this	DT	O	O
pathway	NN	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
source	NN	O	O
of	IN	O	O
individual	JJ	O	O
variability	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
cancer	NN	O	O
susceptibility	NN	O	O
following	VBG	O	O
4-ABP	JJ	O	O
or	CC	O	O
PhIP	JJ	O	O
exposure	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Analysis	NN	O	O
of	IN	O	O
the	DT	O	O
selenoproteome	NN	O	O
identified	VBD	O	O
five	CD	O	O
glutathione	NN	O	O
peroxidases	NNS	O	O
(	(	O	O
GPxs	NNP	O	O
)	)	O	O
in	IN	O	O
mammals	NNS	O	O
:	:	O	O
cytosolic	JJ	O	O
GPx	NNP	O	O
(	(	O	O
cGPx	NN	O	O
,	,	O	O
GPx1	NNP	O	O
)	)	O	O
,	,	O	O
phospholipid	JJ	O	O
hydroperoxide	NN	O	O
GPx	NNP	O	O
(	(	O	O
PHGPX	NNP	O	O
,	,	O	O
GPx4	NNP	O	O
)	)	O	O
,	,	O	O
plasma	JJ	O	O
GPx	NNP	O	O
(	(	O	O
pGPX	NN	O	O
,	,	O	O
GPx3	NNP	O	O
)	)	O	O
,	,	O	O
gastrointestinal	JJ	O	O
GPx	NNP	O	O
(	(	O	O
GI-GPx	NNP	O	O
,	,	O	O
GPx2	NNP	O	O
)	)	O	O
and	CC	O	O
,	,	O	O
in	IN	O	O
humans	NNS	O	O
,	,	O	O
GPx6	NNP	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
restricted	VBN	O	O
to	TO	O	O
the	DT	O	O
olfactory	NN	O	O
system	NN	O	O
.	.	O	O

GPxs	NNP	O	B-enzyme
reduce	VB	O	O
hydroperoxides	NNS	O	O
to	TO	O	O
the	DT	O	O
corresponding	JJ	O	O
alcohols	NNS	O	B-PRODUCT-OF
by	IN	O	O
means	NNS	O	O
of	IN	O	O
glutathione	NN	O	O
(	(	O	O
GSH	NNP	O	O
)	)	O	O
.	.	O	O

They	PRP	O	O
have	VBP	O	O
long	RB	O	O
been	VBN	O	O
considered	VBN	O	O
to	TO	O	O
only	RB	O	O
act	VB	O	O
as	IN	O	O
antioxidant	JJ	O	O
enzymes	NNS	O	O
.	.	O	O

Increasing	VBG	O	O
evidence	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
suggests	VBZ	O	O
that	IN	O	O
nature	NN	O	O
has	VBZ	O	O
not	RB	O	O
created	VBN	O	O
redundant	JJ	O	O
GPxs	NNP	O	O
just	RB	O	O
to	TO	O	O
detoxify	VB	O	O
hydroperoxides	NNS	O	O
.	.	O	O

cGPx	NN	O	O
clearly	RB	O	O
acts	VBZ	O	O
as	IN	O	O
an	DT	O	O
antioxidant	NN	O	O
,	,	O	O
as	IN	O	O
convincingly	RB	O	O
demonstrated	VBN	O	O
in	IN	O	O
GPx1-knockout	NNP	O	O
mice	NN	O	O
.	.	O	O

PHGPx	NNP	O	O
specifically	RB	O	O
interferes	VBZ	O	O
with	IN	O	O
NF-kappaB	NNP	O	O
activation	NN	O	O
by	IN	O	O
interleukin-1	NN	O	O
,	,	O	O
reduces	NNS	O	O
leukotriene	VBP	O	O
and	CC	O	O
prostanoid	JJ	O	O
biosynthesis	NN	O	O
,	,	O	O
prevents	VBZ	O	O
COX-2	JJ	O	O
expression	NN	O	O
,	,	O	O
and	CC	O	O
is	VBZ	O	O
indispensable	JJ	O	O
for	IN	O	O
sperm	JJ	O	O
maturation	NN	O	O
and	CC	O	O
embryogenesis	NN	O	O
.	.	O	O

GI-GPx	NNP	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
not	RB	O	O
exclusively	RB	O	O
expressed	VBN	O	O
in	IN	O	O
the	DT	O	O
gastrointestinal	JJ	O	O
system	NN	O	O
,	,	O	O
is	VBZ	O	O
upregulated	VBN	O	O
in	IN	O	O
colon	NN	O	O
and	CC	O	O
skin	NN	O	O
cancers	NNS	O	O
and	CC	O	O
in	IN	O	O
certain	JJ	O	O
cultured	JJ	O	O
cancer	NN	O	O
cells	NNS	O	O
.	.	O	O

GI-GPx	NNP	O	O
is	VBZ	O	O
a	DT	O	O
target	NN	O	O
for	IN	O	O
Nrf2	NNP	O	O
,	,	O	O
and	CC	O	O
thus	RB	O	O
is	VBZ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
adaptive	JJ	O	O
response	NN	O	O
by	IN	O	O
itself	PRP	O	O
,	,	O	O
while	IN	O	O
PHGPx	NNP	O	O
might	MD	O	O
prevent	VB	O	O
cancer	NN	O	O
by	IN	O	O
interfering	VBG	O	O
with	IN	O	O
inflammatory	JJ	O	O
pathways	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
cGPx	NN	O	O
,	,	O	O
PHGPx	NNP	O	O
and	CC	O	O
GI-GPx	NNP	O	O
have	VBP	O	O
distinct	JJ	O	O
roles	NNS	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
cellular	JJ	O	O
defence	NN	O	O
mechanisms	NNS	O	O
.	.	O	O

Redox	NNP	O	O
sensing	NN	O	O
and	CC	O	O
redox	JJ	O	O
regulation	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
events	NNS	O	O
have	VBP	O	O
become	VBN	O	O
attractive	JJ	O	O
paradigms	NN	O	O
to	TO	O	O
unravel	VB	O	O
the	DT	O	O
specific	NN	O	O
and	CC	O	O
in	IN	O	O
part	NN	O	O
still	RB	O	O
enigmatic	JJ	O	O
roles	NNS	O	O
of	IN	O	O
GPxs	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
molecular	JJ	O	O
bases	NNS	O	O
for	IN	O	O
phosphodiesterase	NN	O	O
5	CD	O	O
(	(	O	O
PDE5	NNP	O	O
)	)	O	O
catalytic-site	JJ	O	O
affinity	NN	O	O
for	IN	O	O
cyclic	JJ	O	O
guanosine	NN	O	O
monophosphate	NN	O	O
(	(	O	O
cGMP	NN	O	O
)	)	O	O
and	CC	O	O
potency	NN	O	O
of	IN	O	O
inhibitors	NNS	O	O
are	VBP	O	O
poorly	RB	O	O
understood	JJ	O	O
.	.	O	O

Cocrystal	JJ	O	O
structures	NNS	O	O
of	IN	O	O
PDE5	NNP	O	O
catalytic	JJ	O	O
(	(	O	O
C	NNP	O	O
)	)	O	O
domain	NN	O	O
with	IN	O	O
inhibitors	NNS	O	O
reveal	VBP	O	O
a	DT	O	O
hydrogen	NN	O	O
bond	NN	O	O
and	CC	O	O
hydrophobic	JJ	O	O
interactions	NNS	O	O
with	IN	O	O
Tyr-612	NNP	O	O
,	,	O	O
hydrogen	NN	O	O
bonds	NNS	O	O
with	IN	O	O
Gln-817	NNP	O	O
,	,	O	O
a	DT	O	O
hydrophobic	JJ	O	O
clamp	NN	O	O
formed	VBN	O	O
by	IN	O	O
Phe-820	NNP	O	O
and	CC	O	O
Val-782	NNP	O	O
,	,	O	O
and	CC	O	O
contacts	NNS	O	O
with	IN	O	O
His-613	NNP	O	O
,	,	O	O
Leu-765	NNP	O	O
,	,	O	O
and	CC	O	O
Phe-786	NNP	O	O
[	NNP	O	O
Sung	NNP	O	O
et	FW	O	O
al	NN	O	O
.	.	O	O

(	(	O	O
2003	CD	O	O
)	)	O	O
Nature	NN	O	O
425	CD	O	O
,	,	O	O
98-102	CD	O	O
;	:	O	O
Huai	NNP	O	O
et	FW	O	O
al	NN	O	O
.	.	O	O

(	(	O	O
2004	CD	O	O
)	)	O	O
J.	NNP	O	O
Biol	NNP	O	O
.	.	O	O

Chem	NNP	O	O
.	.	O	O

279	CD	O	O
,	,	O	O
13095-13101	JJ	O	O
]	NN	O	O
.	.	O	O

Present	JJ	O	O
results	NNS	O	O
of	IN	O	O
point	JJ	O	O
mutations	NNS	O	O
of	IN	O	O
full-length	JJ	O	O
PDE5	NNP	O	O
showed	VBD	O	O
that	IN	O	O
maximum	JJ	O	O
catalysis	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
2650-fold	JJ	O	O
in	IN	O	O
H613A	NNP	O	O
and	CC	O	O
55-fold	JJ	O	O
in	IN	O	O
F820A	NNP	O	O
.	.	O	O

Catalytic-site	JJ	O	O
affinities	NNS	O	O
for	IN	O	O
cGMP	NN	O	O
,	,	O	O
vardenafil	NN	O	O
,	,	O	O
sildenafil	NN	O	O
,	,	O	O
tadalafil	NN	O	B-SUBSTRATE
,	,	O	O
or	CC	O	O
3-isobutyl-1-methylxanthine	JJ	O	O
(	(	O	O
IBMX	NNP	O	O
)	)	O	O
were	VBD	O	O
respectively	RB	O	O
weakened	VBN	O	O
14-	CD	O	O
,	,	O	O
123-	CD	O	O
,	,	O	O
30-	CD	O	O
,	,	O	O
51-	JJ	O	O
,	,	O	O
and	CC	O	O
43-fold	JJ	O	O
for	IN	O	O
Y612A	NNP	O	O
;	:	O	O
63-	JJ	O	O
,	,	O	O
511-	JJ	O	O
,	,	O	O
43-	JJ	O	O
,	,	O	O
95-	JJ	O	O
and	CC	O	O
61-fold	JJ	O	O
for	IN	O	O
Q817A	NNP	O	B-enzyme
;	:	O	O
and	CC	O	O
59-	JJ	O	O
,	,	O	O
448-	JJ	O	O
,	,	O	O
71-	JJ	O	O
,	,	O	O
137-	JJ	O	O
,	,	O	O
and	CC	O	O
93-fold	JJ	O	O
for	IN	O	O
F820A	NNP	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
indicate	NN	O	O
that	IN	O	O
these	DT	O	O
three	CD	O	O
amino	NN	O	O
acids	NNS	O	O
are	VBP	O	O
major	JJ	O	O
determinants	NNS	O	O
of	IN	O	O
affinity	NN	O	O
for	IN	O	O
cGMP	NN	O	O
and	CC	O	O
potency	NN	O	O
of	IN	O	O
selective	JJ	O	O
and	CC	O	O
nonselective	JJ	O	O
inhibitors	NNS	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
higher	JJR	O	O
vardenafil	NN	O	O
potency	NN	O	O
over	IN	O	O
sildenafil	NN	O	O
and	CC	O	O
tadalafil	JJ	O	O
results	NNS	O	O
from	IN	O	O
stronger	JJR	O	O
contacts	NNS	O	O
with	IN	O	O
Tyr-612	NNP	O	O
,	,	O	O
Gln-817	NNP	O	O
,	,	O	O
and	CC	O	O
Phe-820	NNP	O	O
.	.	O	O

Affinity	NN	O	O
of	IN	O	O
V782A	NNP	O	O
for	IN	O	O
cGMP	NN	O	O
,	,	O	O
vardenafil	NN	O	O
,	,	O	O
sildenafil	NN	O	O
,	,	O	O
tadalafil	NN	O	O
,	,	O	O
or	CC	O	O
IBMX	NNP	O	O
was	VBD	O	O
reduced	VBN	O	O
5.5-	JJ	O	O
,	,	O	O
23-	JJ	O	O
,	,	O	O
10-	JJ	O	O
,	,	O	O
3-	JJ	O	O
,	,	O	O
and	CC	O	O
12-fold	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Change	NN	O	O
in	IN	O	O
affinity	NN	O	O
for	IN	O	O
cGMP	NN	O	O
,	,	O	O
vardenafil	NN	O	O
,	,	O	O
sildenafil	NN	O	O
,	,	O	O
or	CC	O	O
IBMX	NNP	O	O
in	IN	O	O
Y612F	NNP	O	O
,	,	O	O
H613A	NNP	O	O
,	,	O	O
L765A	NNP	O	O
,	,	O	O
or	CC	O	O
F786A	NNP	O	O
was	VBD	O	O
less	RBR	O	O
,	,	O	O
but	CC	O	O
affinity	NN	O	O
of	IN	O	O
H613A	NNP	O	O
or	CC	O	O
F786A	NNP	O	O
for	IN	O	O
tadalafil	NN	O	O
was	VBD	O	O
weakened	VBN	O	O
37-	JJ	O	O
and	CC	O	O
17-fold	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
quantify	VBP	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
PDE5	NNP	O	O
catalytic-site	JJ	O	O
residues	NNS	O	O
for	IN	O	O
cGMP	NN	O	O
and	CC	O	O
inhibitors	NNS	O	O
,	,	O	O
indicate	VBP	O	O
that	IN	O	O
Tyr-612	NNP	O	O
,	,	O	O
Gln-817	NNP	O	O
,	,	O	O
and	CC	O	O
Phe-820	NNP	O	O
are	VBP	O	O
the	DT	O	O
most	RBS	O	O
important	JJ	O	O
cGMP	NN	O	O
or	CC	O	O
inhibitor	NN	O	O
contacts	NNS	O	O
studied	VBN	O	O
,	,	O	O
and	CC	O	O
identify	VB	O	O
residues	NNS	O	O
that	WDT	O	O
contribute	VBP	O	O
to	TO	O	O
selectivity	NN	O	O
among	IN	O	O
different	JJ	O	O
classes	NNS	O	O
of	IN	O	O
inhibitors	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

A	DT	O	O
complex	JJ	O	O
dynamic	JJ	O	O
ultradian	JJ	O	O
rhythm	NN	O	O
underlies	VBZ	O	O
the	DT	O	O
hypothalamic-pituitary-adrenal	JJ	O	O
(	(	O	O
HPA	NNP	O	O
)	)	O	O
circadian	JJ	O	O
rhythm	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
investigated	VBN	O	O
in	IN	O	O
normal	JJ	O	O
human	JJ	O	O
male	NN	O	O
subjects	VBZ	O	O
the	DT	O	O
importance	NN	O	O
,	,	O	O
site	NN	O	O
of	IN	O	O
action	NN	O	O
,	,	O	O
and	CC	O	O
receptor-mediated	JJ	O	O
processes	NNS	O	O
involved	VBN	O	O
in	IN	O	O
rapid	JJ	O	O
basal	NN	O	O
corticosteroid	JJ	O	O
feedback	NN	O	O
and	CC	O	O
its	PRP$	O	O
interaction	NN	O	O
with	IN	O	O
corticotrophin	JJ	O	O
releasing	VBG	O	O
hormone	NN	O	O
(	(	O	O
CRH	NNP	O	O
)	)	O	O
drive	NN	O	O
.	.	O	O

Pro-opiomelanocortin	NNP	O	O
(	(	O	O
POMC	NNP	O	O
)	)	O	O
,	,	O	O
ACTH	NNP	O	O
,	,	O	O
and	CC	O	O
cortisol	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
every	DT	O	O
10	CD	O	O
min	NN	O	O
from	IN	O	O
healthy	JJ	O	O
males	NNS	O	O
during	IN	O	O
the	DT	O	O
awakening	JJ	O	O
period	NN	O	O
or	CC	O	O
late	JJ	O	O
afternoon	NN	O	O
using	VBG	O	O
an	DT	O	O
automated	VBN	O	O
blood	NN	O	O
sampling	VBG	O	O
system	NN	O	O
.	.	O	O

Mathematical	JJ	O	O
modeling	NN	O	O
into	IN	O	O
discrete	JJ	O	O
pulses	NNS	O	O
of	IN	O	O
activity	NN	O	O
revealed	VBD	O	O
that	IN	O	O
intravenous	JJ	O	O
infusion	NN	O	O
of	IN	O	O
the	DT	O	O
synthetic	JJ	O	O
mixed	JJ	O	O
glucocorticoid/mineralocorticoid	JJ	O	O
agonist	NN	O	O
prednisolone	NN	O	O
produced	VBD	O	O
rapid	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
ACTH	NNP	O	O
and	CC	O	O
cortisol	JJ	O	O
pulsatility	NN	O	O
within	IN	O	O
30	CD	O	O
min	NN	O	O
in	IN	O	O
the	DT	O	O
morning	NN	O	O
and	CC	O	O
afternoon	NN	O	O
.	.	O	O

Any	DT	O	O
pulse	NN	O	O
that	WDT	O	O
had	VBD	O	O
commenced	VBN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
injection	NN	O	O
was	VBD	O	O
unaffected	VBN	O	O
,	,	O	O
and	CC	O	O
subsequent	JJ	O	O
pulsatility	NN	O	O
was	VBD	O	O
inhibited	VBN	O	O
.	.	O	O

Prednisolone	NN	O	O
also	RB	O	O
inhibited	VBD	O	O
ACTH	NNP	O	O
and	CC	O	O
cortisol	JJ	O	B-PRODUCT-OF
secretion	NN	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
exogenous	JJ	O	O
CRH	NNP	O	B-enzyme
stimulation	NN	O	O
,	,	O	O
inferring	VBG	O	O
rapid	JJ	O	O
feedback	JJ	O	O
inhibition	NN	O	O
at	IN	O	O
the	DT	O	O
anterior	JJ	O	O
pituitary	NN	O	O
.	.	O	O

Circulating	VBG	O	O
POMC	NNP	O	O
peptide	NN	O	O
concentrations	NNS	O	O
were	VBD	O	O
unaffected	JJ	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
the	DT	O	O
rapid	JJ	O	O
corticosteroid	JJ	O	O
inhibitory	NN	O	O
effect	NN	O	O
specifically	RB	O	O
targeted	VBD	O	O
ACTH	NNP	O	O
secretion	NN	O	O
from	IN	O	O
pituitary	JJ	O	O
corticotrophs	NN	O	O
.	.	O	O

Prednisolone	NNP	O	O
fast	VBD	O	O
feedback	NN	O	O
was	VBD	O	O
only	RB	O	O
reduced	VBN	O	O
by	IN	O	O
glucocorticoid	JJ	O	O
receptor	NN	O	O
antagonist	NN	O	O
pretreatment	NN	O	O
and	CC	O	O
not	RB	O	O
by	IN	O	O
mineralocorticoid	JJ	O	O
receptor	NN	O	O
antagonism	NN	O	O
,	,	O	O
suggesting	VBG	O	O
a	DT	O	O
glucocorticoid	JJ	O	O
receptor-mediated	JJ	O	O
pathway	NN	O	O
.	.	O	O

The	DT	O	O
intravenous	JJ	O	O
prednisolone	NN	O	O
suppression	NN	O	O
test	NN	O	O
provides	VBZ	O	O
a	DT	O	O
powerful	JJ	O	O
new	JJ	O	O
tool	NN	O	O
to	TO	O	O
investigate	VB	O	O
HPA	NNP	O	O
abnormalities	NNS	O	O
underlying	VBG	O	O
metabolic	NN	O	O
and	CC	O	O
psychiatric	JJ	O	O
disease	NN	O	O
states	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Studies	NNS	O	O
in	IN	O	O
microsomal	JJ	O	O
and	CC	O	O
reconstituted	JJ	O	O
systems	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
one	CD	O	O
cytochrome	NN	O	O
P450	NNP	O	O
isoform	NN	O	O
can	MD	O	O
significantly	RB	O	O
influence	VB	O	O
the	DT	O	O
catalytic	JJ	O	O
activity	NN	O	O
of	IN	O	O
another	DT	O	O
isoform	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
assessed	VBD	O	O
whether	IN	O	O
CYP2E1	NNP	O	O
could	MD	O	O
influence	VB	O	O
the	DT	O	O
catalytic	JJ	O	O
activity	NN	O	O
of	IN	O	O
CYP2B4	NNP	O	O
under	IN	O	O
steady-state	JJ	O	O
turnover	NN	O	O
conditions	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
CYP2E1	NNP	O	O
inhibits	VBZ	O	O
CYP2B4-mediated	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
benzphetamine	NN	O	B-SUBSTRATE
(	(	O	O
BNZ	NNP	O	B-SUBSTRATE
)	)	O	O
with	IN	O	O
a	DT	O	O
K	NNP	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
of	IN	O	O
0.04	CD	O	O
M	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
CYP2B4	NNP	O	O
is	VBZ	O	O
not	RB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
CYP2E1-mediated	JJ	O	O
p-nitrophenol	JJ	O	B-SUBSTRATE
hydroxylation	NN	O	O
.	.	O	O

When	WRB	O	O
these	DT	O	O
inhibition	NN	O	O
studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
with	IN	O	O
the	DT	O	O
artificial	JJ	O	O
oxidant	JJ	O	O
tert-butyl	JJ	O	O
hydroperoxide	NN	O	O
,	,	O	O
CYP2E1	NNP	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
inhibit	VB	O	O
CYP2B4	NNP	O	O
activity	NN	O	O
.	.	O	O

Determinations	NNS	O	O
of	IN	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
and	CC	O	O
k	$	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
of	IN	O	O
CYP2B4	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
increasing	VBG	O	O
concentrations	NNS	O	O
of	IN	O	O
CYP2E1	NNP	O	O
revealed	VBD	O	O
a	DT	O	O
mixed	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
CYP2B4	NNP	O	O
by	IN	O	O
CYP2E1	NNP	O	O
.	.	O	O

At	IN	O	O
low	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
CYP2E1	NNP	O	O
,	,	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
of	IN	O	O
CYP2B4	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
increased	VBD	O	O
up	RP	O	O
to	TO	O	O
23-fold	JJ	O	O
with	IN	O	O
virtually	RB	O	O
no	DT	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
k	NN	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
reaction	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
at	IN	O	O
higher	JJR	O	O
concentrations	NNS	O	O
of	IN	O	O
CYP2E1	NNP	O	O
,	,	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
of	IN	O	O
CYP2B4	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
decreased	VBD	O	O
to	TO	O	O
levels	NNS	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
CYP2E1	NNP	O	O
and	CC	O	O
the	DT	O	O
k	NN	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
also	RB	O	O
decreased	VBN	O	O
by	IN	O	O
11-fold	JJ	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
CYP2E1	NNP	O	O
increased	VBD	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
of	IN	O	O
CYP2B4	NNP	O	O
for	IN	O	O
BNZ	NNP	O	O
by	IN	O	O
8-fold	JJ	O	O
and	CC	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
did	VBD	O	O
not	RB	O	O
decrease	VB	O	O
to	TO	O	O
its	PRP$	O	O
original	JJ	O	O
value	NN	O	O
when	WRB	O	O
saturating	VBG	O	O
concentrations	NNS	O	O
of	IN	O	O
CPR	NNP	O	O
were	VBD	O	O
used	VBN	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
individual	JJ	O	O
apparent	NN	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
values	NNS	O	O
of	IN	O	O
CYP2B4	NNP	O	O
and	CC	O	O
CYP2E1	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
are	VBP	O	O
similar	JJ	O	O
,	,	O	O
the	DT	O	O
apparent	JJ	O	O
K	NNP	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
of	IN	O	O
CYP2E1	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
CYP2B4	NNP	O	O
decreased	VBD	O	O
significantly	RB	O	O
,	,	O	O
thus	RB	O	O
suggesting	VBG	O	O
that	IN	O	O
CYP2B4	NNP	O	O
enhances	VBZ	O	O
the	DT	O	O
affinity	NN	O	O
of	IN	O	O
CYP2E1	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
and	CC	O	O
this	DT	O	O
may	MD	O	O
allow	VB	O	O
CYP2E1	NNP	O	O
to	TO	O	O
out-compete	JJ	O	O
CYP2B4	NNP	O	O
for	IN	O	O
CPR	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Oxidation	NN	O	O
of	IN	O	O
membrane	NN	O	O
phospholipids	NNS	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
inflammation	NN	O	O
,	,	O	O
neurodegenerative	JJ	O	O
disease	NN	O	O
,	,	O	O
and	CC	O	O
cancer	NN	O	O
.	.	O	O

Oxyradical	JJ	O	O
damage	NN	O	O
to	TO	O	O
phospholipids	NNS	O	O
results	NNS	O	O
in	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
reactive	JJ	O	O
aldehydes	NNS	O	O
that	IN	O	O
adduct	NN	O	O
proteins	NNS	O	O
and	CC	O	O
modulate	VB	O	O
their	PRP$	O	O
function	NN	O	O
.	.	O	O

4-Hydroxynonenal	JJ	O	O
(	(	O	O
HNE	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
common	JJ	O	O
product	NN	O	O
of	IN	O	O
oxidative	JJ	O	O
damage	NN	O	O
to	TO	O	O
lipids	NNS	O	O
,	,	O	O
adducts	NNS	O	O
proteins	NNS	O	O
at	IN	O	O
exposed	JJ	O	O
Cys	NNP	O	O
,	,	O	O
His	PRP$	O	O
,	,	O	O
or	CC	O	O
Lys	NNP	O	O
residues	NNS	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
demonstrate	VBP	O	O
that	IN	O	O
peptidyl-prolyl	JJ	O	B-enzyme
cis/trans-isomerase	JJ	O	I-enzyme
A1	NNP	O	O
(	(	O	O
Pin1	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
an	DT	O	O
enzyme	NN	O	O
that	WDT	O	O
catalyzes	VBZ	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
the	DT	O	O
peptide	JJ	O	O
bond	NN	O	O
of	IN	O	O
pSer/pThr-Pro	JJ	O	O
moieties	NNS	O	O
in	IN	O	O
signaling	VBG	O	O
proteins	NNS	O	O
from	IN	O	O
cis	NN	O	O
to	TO	O	O
trans	NNS	O	O
,	,	O	O
is	VBZ	O	O
highly	RB	O	O
susceptible	JJ	O	O
to	TO	O	O
HNE	NNP	O	O
modification	NN	O	O
.	.	O	O

Incubation	NN	O	O
of	IN	O	O
purified	JJ	O	O
Pin1	NNP	O	O
with	IN	O	O
HNE	NNP	O	O
followed	VBN	O	O
by	IN	O	O
MALDI-TOF/TOF	NNP	O	O
mass	NN	O	O
spectrometry	NN	O	O
resulted	VBD	O	O
in	IN	O	O
detection	NN	O	O
of	IN	O	O
Michael	NNP	O	O
adducts	NNS	O	O
at	IN	O	O
the	DT	O	O
active	JJ	O	O
site	NN	O	O
residues	NNS	O	O
His-157	NNP	O	O
and	CC	O	O
Cys-113	NNP	O	O
.	.	O	O

Time	NNP	O	O
and	CC	O	O
concentration	NN	O	O
dependencies	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
Cys-113	NNP	O	O
is	VBZ	O	O
the	DT	O	O
primary	JJ	O	O
site	NN	O	O
of	IN	O	O
HNE	NNP	O	O
modification	NN	O	O
.	.	O	O

Pin1	NNP	O	O
was	VBD	O	O
adducted	VBN	O	O
in	IN	O	O
MDA-MB-231	NNP	O	O
breast	NN	O	O
cancer	NN	O	O
cells	NNS	O	O
treated	VBN	O	O
with	IN	O	O
8-alkynyl-HNE	JJ	O	O
as	IN	O	O
judged	VBN	O	O
by	IN	O	O
click	JJ	O	O
chemistry	NN	O	O
conjugation	NN	O	O
with	IN	O	O
biotin	NN	O	O
followed	VBN	O	O
by	IN	O	O
streptavidin-based	JJ	O	O
pulldown	NN	O	O
and	CC	O	O
Western	JJ	O	O
blotting	VBG	O	O
with	IN	O	O
anti-Pin1	JJ	O	O
antibody	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
orbitrap	PRP	O	O
MS	NNP	O	O
data	NNS	O	O
support	NN	O	O
the	DT	O	O
adduction	NN	O	O
of	IN	O	O
Cys-113	NNP	O	O
in	IN	O	O
the	DT	O	O
Pin1	NNP	O	O
active	JJ	O	O
site	NN	O	O
upon	IN	O	O
HNE	NNP	O	O
treatment	NN	O	O
of	IN	O	O
MDA-MB-231	NNP	O	O
cells	NNS	O	O
.	.	O	O

siRNA	JJ	O	O
knockdown	NN	O	O
of	IN	O	O
Pin1	NNP	O	O
in	IN	O	O
MDA-MB-231	NNP	O	O
cells	NNS	O	O
partially	RB	O	O
protected	VBD	O	O
the	DT	O	O
cells	NNS	O	O
from	IN	O	O
HNE-induced	NNP	O	O
toxicity	NN	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
Pin1	NNP	O	O
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
molecular	JJ	O	O
target	NN	O	O
for	IN	O	O
the	DT	O	O
chemopreventive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
green	JJ	O	O
tea	NN	O	O
polyphenols	NNS	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
establishes	VBZ	O	O
that	IN	O	O
it	PRP	O	O
is	VBZ	O	O
also	RB	O	O
a	DT	O	O
target	NN	O	O
for	IN	O	O
electrophilic	JJ	O	O
modification	NN	O	O
by	IN	O	O
products	NNS	O	O
of	IN	O	O
lipid	JJ	O	O
peroxidation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
sex	NN	O	O
,	,	O	O
ethnicity	NN	O	O
,	,	O	O
and	CC	O	O
genetic	JJ	O	O
polymorphism	NN	O	O
on	IN	O	O
hepatic	JJ	O	O
CYP2B6	NNP	O	O
(	(	O	O
cytochrome	JJ	O	O
P450	NNP	O	O
2B6	CD	O	O
)	)	O	O
expression	NN	O	O
and	CC	O	O
activity	NN	O	O
were	VBD	O	O
previously	RB	O	O
demonstrated	VBN	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

Race/ethnic	JJ	O	O
differences	NNS	O	O
in	IN	O	O
CYP2B6	NNP	O	O
genotype	NN	O	O
and	CC	O	O
phenotype	NN	O	O
were	VBD	O	O
observed	VBN	O	O
only	RB	O	O
in	IN	O	O
women	NNS	O	O
.	.	O	O

To	TO	O	O
identify	VB	O	O
important	JJ	O	O
covariates	NNS	O	O
associated	VBN	O	O
with	IN	O	O
interindividual	JJ	O	O
variation	NN	O	O
in	IN	O	O
CYP2B6	NNP	O	O
activity	NN	O	O
in	IN	O	O
vivo	NN	O	O
,	,	O	O
we	PRP	O	O
evaluated	VBD	O	O
these	DT	O	O
effects	NNS	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
using	VBG	O	O
bupropion	NN	O	B-SUBSTRATE
(	(	O	O
Wellbutrin	NNP	O	B-SUBSTRATE
SR	NNP	O	I-SUBSTRATE
GlaxoSmithKline	NNP	O	O
,	,	O	O
Research	NNP	O	O
Triangle	NNP	O	O
Park	NNP	O	O
,	,	O	O
NC	NNP	O	O
)	)	O	O
as	IN	O	O
a	DT	O	O
CYP2B6	NNP	O	B-enzyme
probe	NN	O	O
substrate	NN	O	O
.	.	O	O

A	DT	O	O
fixed	JJ	O	O
150-mg	JJ	O	O
oral	JJ	O	O
sustained-release	NN	O	O
dose	NN	O	O
of	IN	O	O
bupropion	NN	O	O
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
100	CD	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
comprising	VBG	O	O
four	CD	O	O
sex/ethnicity	NN	O	O
cohorts	NNS	O	O
(	(	O	O
n	JJ	O	O
=	RB	O	O
25	CD	O	O
each	DT	O	O
)	)	O	O
:	:	O	O
Caucasian	JJ	O	O
men	NNS	O	O
and	CC	O	O
Caucasian	NNP	O	O
,	,	O	O
African	JJ	O	O
American	NNP	O	O
,	,	O	O
and	CC	O	O
Hispanic	JJ	O	O
women	NNS	O	O
.	.	O	O

Blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
0	CD	O	O
and	CC	O	O
6	CD	O	O
hours	NNS	O	O
postdose	RB	O	O
for	IN	O	O
the	DT	O	O
measurement	NN	O	O
of	IN	O	O
serum	JJ	O	O
bupropion	NN	O	O
(	(	O	O
BU	NNP	O	O
)	)	O	O
and	CC	O	O
hydroxybupropion	NN	O	O
(	(	O	O
HB	NNP	O	O
)	)	O	O
concentrations	NNS	O	O
.	.	O	O

Whole	JJ	O	O
blood	NN	O	O
was	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
baseline	NN	O	O
for	IN	O	O
CYP2B6	NNP	O	O
genotyping	NN	O	O
.	.	O	O

To	TO	O	O
characterize	VB	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
CYP2B6	NNP	O	O
activity	NN	O	O
and	CC	O	O
ethnicity	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
and	CC	O	O
genotype	NN	O	O
when	WRB	O	O
accounting	NN	O	O
for	IN	O	O
serum	JJ	O	O
BU	NNP	O	O
concentrations	NNS	O	O
(	(	O	O
dose-adjusted	JJ	O	O
log	NN	O	O
(	(	O	O
10	CD	O	O
)	)	O	O
-transformed	VBN	O	O
)	)	O	O
,	,	O	O
analysis	NN	O	O
of	IN	O	O
covariance	NN	O	O
model	NN	O	O
was	VBD	O	O
fitted	VBN	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
dependent	NN	O	O
variable	NN	O	O
was	VBD	O	O
CYP2B6	NNP	O	O
activity	NN	O	O
represented	VBD	O	O
as	IN	O	O
the	DT	O	O
log	NN	O	O
(	(	O	O
10	CD	O	O
)	)	O	O
-transformed	VBN	O	O
,	,	O	O
metabolic	JJ	O	O
ratio	NN	O	O
of	IN	O	O
HB	NNP	O	O
to	TO	O	O
BU	NNP	O	O
concentrations	NNS	O	O
.	.	O	O

Several	JJ	O	O
CYP2B6	NNP	O	O
polymorphisms	NNS	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
CYP2B6	NNP	O	O
activity	NN	O	O
.	.	O	O

Evidence	NN	O	O
of	IN	O	O
dependence	NN	O	O
of	IN	O	O
CYP2B6	NNP	O	O
activity	NN	O	O
on	IN	O	O
ethnicity	NN	O	O
or	CC	O	O
genotype-by-ethnicity	NN	O	O
interactions	NNS	O	O
was	VBD	O	O
not	RB	O	O
detected	VBN	O	O
in	IN	O	O
women	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
CYP2B6	NNP	O	B-enzyme
genotype	NN	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
important	JJ	O	O
patient	NN	O	O
variable	NN	O	O
for	IN	O	O
predicting	VBG	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
CYP2B6	NNP	O	B-enzyme
activity	NN	O	O
in	IN	O	O
women	NNS	O	O
,	,	O	O
when	WRB	O	O
measured	VBN	O	O
by	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
bupropion	NN	O	B-SUBSTRATE
.	.	O	O

The	DT	O	O
bupropion	NN	O	B-SUBSTRATE
metabolic	NN	O	O
ratio	NN	O	O
appears	VBZ	O	O
to	TO	O	O
detect	VB	O	O
known	JJ	O	O
differences	NNS	O	O
in	IN	O	O
CYP2B6	NNP	O	B-enzyme
activity	NN	O	O
associated	VBN	O	O
with	IN	O	O
genetic	JJ	O	O
polymorphism	NN	O	O
,	,	O	O
across	IN	O	O
different	JJ	O	O
ethnic	JJ	O	O
groups	NNS	O	O
.	.	O	O

Prospective	JJ	O	O
studies	NNS	O	O
will	MD	O	O
be	VB	O	O
needed	VBN	O	O
to	TO	O	O
validate	VB	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
bupropion	NN	O	O
as	IN	O	O
a	DT	O	O
probe	NN	O	O
substrate	NN	O	O
for	IN	O	O
clinical	JJ	O	O
use	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Leukotrienes	NNS	O	O
(	(	O	O
LT	NNP	O	O
's	POS	O	O
)	)	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
play	VB	O	O
a	DT	O	O
physiological	JJ	O	O
role	NN	O	O
in	IN	O	O
inflammatory	JJ	O	O
immune	JJ	O	O
response	NN	O	O
.	.	O	O

Leukotriene	VB	O	B-enzyme
A	NNP	O	I-enzyme
(	(	O	I-enzyme
4	CD	O	I-enzyme
)	)	O	I-enzyme
hydrolase	NN	O	O
(	(	O	O
LTA	NNP	O	B-enzyme
(	(	O	O
4	CD	O	O
)	)	O	O
H	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
cystolic	JJ	O	O
enzyme	NN	O	O
that	WDT	O	O
stereospecifically	RB	O	O
catalyzes	VBZ	O	O
the	DT	O	O
transformation	NN	O	O
of	IN	O	O
LTA	NNP	O	B-SUBSTRATE
(	(	O	O
4	CD	O	O
)	)	O	O
to	TO	O	O
LTB	NNP	O	B-PRODUCT-OF
(	(	O	O
4	CD	O	O
)	)	O	O
.	.	O	O

LTB	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
known	JJ	O	O
pro-inflammatory	JJ	O	O
mediator	NN	O	O
.	.	O	O

This	DT	O	O
paper	NN	O	O
describes	VBZ	O	O
the	DT	O	O
identification	NN	O	O
and	CC	O	O
synthesis	NN	O	O
of	IN	O	O
substituted	JJ	O	O
benzofurans	NNS	O	O
as	IN	O	O
LTH	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
H	NNP	O	O
inhibitors	NNS	O	O
.	.	O	O

The	DT	O	O
benzofuran	NN	O	O
series	NN	O	O
demonstrated	VBD	O	O
reduced	JJ	O	O
mouse	NN	O	O
and	CC	O	O
human	JJ	O	O
whole	JJ	O	O
blood	NN	O	O
LTB	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
levels	NNS	O	O
in	IN	O	O
vitro	NN	O	O
and	CC	O	O
led	VBD	O	O
to	TO	O	O
the	DT	O	O
identification	NN	O	O
one	CD	O	O
analog	NN	O	O
for	IN	O	O
advanced	JJ	O	O
profiling	NN	O	O
.	.	O	O

Benzofuran	NNP	O	O
28	CD	O	O
showed	VBD	O	O
dose	JJ	O	O
responsive	JJ	O	O
target	NN	O	O
engagement	NN	O	O
and	CC	O	O
provides	VBZ	O	O
a	DT	O	O
useful	JJ	O	O
tool	NN	O	O
to	TO	O	O
explore	VB	O	O
a	DT	O	O
LTA	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
H	NNP	O	O
inhibitor	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
inflammatory	NN	O	O
diseases	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
asthma	NN	O	O
and	CC	O	O
inflammatory	JJ	O	O
bowel	NN	O	O
disease	NN	O	O
(	(	O	O
IBD	NNP	O	O
)	)	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Elevated	VBN	O	O
fasting	VBG	O	O
blood	NN	O	O
glucose	NN	O	O
(	(	O	O
FBG	NNP	O	O
)	)	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
increased	VBN	O	O
risk	NN	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
type	NN	O	O
2	CD	O	O
diabetes	NNS	O	O
and	CC	O	O
cardiovascular-associated	JJ	O	O
mortality	NN	O	O
.	.	O	O

Genome-wide	NNP	O	O
association	NN	O	O
studies	NNS	O	O
(	(	O	O
GWAS	NNP	O	O
)	)	O	O
have	VBP	O	O
linked	VBN	O	O
polymorphisms	NNS	O	O
in	IN	O	O
G6PC2	NNP	O	O
with	IN	O	O
variations	NNS	O	O
in	IN	O	O
FBG	NNP	O	O
and	CC	O	O
body	NN	O	O
fat	NN	O	O
,	,	O	O
although	IN	O	O
not	RB	O	O
insulin	JJ	O	O
sensitivity	NN	O	O
or	CC	O	O
glucose	JJ	O	O
tolerance	NN	O	O
.	.	O	O

G6PC2	NNP	O	O
encodes	VBZ	O	O
an	DT	O	O
islet-specific	JJ	O	O
,	,	O	O
endoplasmic	JJ	O	O
reticulum-resident	JJ	O	O
glucose-6-phosphatase	JJ	O	O
catalytic	JJ	O	O
subunit	NN	O	O
.	.	O	O

A	DT	O	O
combination	NN	O	O
of	IN	O	O
in	IN	O	O
situ	NN	O	O
perfused	VBN	O	O
pancreas	NNS	O	O
,	,	O	O
in	IN	O	O
vitro	NN	O	O
isolated	JJ	O	O
islet	NN	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
vivo	JJ	O	O
analyses	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
explore	VB	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
G6pc2	NNP	O	O
in	IN	O	O
mice	NN	O	O
.	.	O	O

G6pc2	NNP	O	O
deletion	NN	O	O
had	VBD	O	O
little	JJ	O	O
effect	NN	O	O
on	IN	O	O
insulin	NN	O	O
sensitivity	NN	O	O
and	CC	O	O
glucose	JJ	O	O
tolerance	NN	O	O
,	,	O	O
whereas	IN	O	O
body	NN	O	O
fat	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
female	JJ	O	O
G6pc2	NNP	O	O
knockout	NN	O	O
(	(	O	O
KO	NNP	O	O
)	)	O	O
mice	NN	O	O
on	IN	O	O
both	DT	O	O
a	DT	O	O
chow	NN	O	O
and	CC	O	O
high-fat	JJ	O	O
diet	NN	O	O
,	,	O	O
observations	NNS	O	O
that	WDT	O	O
are	VBP	O	O
all	DT	O	O
consistent	JJ	O	O
with	IN	O	O
human	JJ	O	O
GWAS	NNP	O	O
data	NN	O	O
.	.	O	O

G6pc2	NNP	O	O
deletion	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
leftward	JJ	O	O
shift	NN	O	O
in	IN	O	O
the	DT	O	O
dose-response	JJ	O	O
curve	NN	O	O
for	IN	O	O
glucose-stimulated	JJ	O	O
insulin	NN	O	O
secretion	NN	O	O
(	(	O	O
GSIS	NNP	O	O
)	)	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
consequence	NN	O	O
,	,	O	O
under	IN	O	O
fasting	VBG	O	O
conditions	NNS	O	O
in	IN	O	O
which	WDT	O	O
plasma	VBP	O	O
insulin	NN	O	O
levels	NNS	O	O
were	VBD	O	O
identical	JJ	O	O
,	,	O	O
blood	NN	O	O
glucose	NN	O	O
levels	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
G6pc2	NNP	O	O
KO	NNP	O	O
mice	NN	O	O
,	,	O	O
again	RB	O	O
consistent	JJ	O	O
with	IN	O	O
human	JJ	O	O
GWAS	NNP	O	O
data	NN	O	O
.	.	O	O

Glucose-6-phosphatase	NNP	O	O
activity	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
,	,	O	O
whereas	IN	O	O
basal	JJ	O	O
cytoplasmic	JJ	O	O
calcium	NN	O	O
levels	NNS	O	O
were	VBD	O	O
elevated	VBN	O	O
in	IN	O	O
islets	NNS	O	O
isolated	VBN	O	O
from	IN	O	O
G6pc2	NNP	O	O
KO	NNP	O	O
mice	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
G6pc2	NNP	O	B-enzyme
represents	VBZ	O	O
a	DT	O	O
novel	NN	O	O
,	,	O	O
negative	JJ	O	O
regulator	NN	O	O
of	IN	O	O
basal	NN	O	O
GSIS	NNP	O	O
that	WDT	O	O
acts	VBZ	O	O
by	IN	O	O
hydrolyzing	VBG	O	O
glucose-6-phosphate	NN	O	B-SUBSTRATE
,	,	O	O
thereby	RB	O	O
reducing	VBG	O	O
glycolytic	JJ	O	O
flux	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Tinospora	NNP	O	O
cordifolia	NN	O	O
is	VBZ	O	O
a	DT	O	O
well	RB	O	O
reported	VBN	O	O
plant	NN	O	O
possessing	VBG	O	O
numerous	JJ	O	O
medicinal	JJ	O	O
values	NNS	O	O
including	VBG	O	O
anti-diabetic	JJ	O	O
property	NN	O	O
.	.	O	O

Aim	NNP	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
is	VBZ	O	O
to	TO	O	O
study	VB	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
Tinospora	NNP	O	O
cordifolia	NN	O	O
and	CC	O	O
its	PRP$	O	O
active	JJ	O	O
compound	NN	O	O
in	IN	O	O
differentiated	JJ	O	O
myocytes	NNS	O	O
,	,	O	O
L6	NNP	O	O
cells	NNS	O	O
.	.	O	O

Key	NNP	O	O
marker	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
in	IN	O	O
cells	NNS	O	O
is	VBZ	O	O
the	DT	O	O
insulin	NN	O	O
dependent	JJ	O	O
glucose	JJ	O	O
transporter-4	JJ	O	O
(	(	O	O
Glut-4	NNP	O	O
)	)	O	O
which	WDT	O	O
also	RB	O	O
responds	VBZ	O	O
to	TO	O	O
exogenous	JJ	O	O
chemicals	NNS	O	O
,	,	O	O
and	CC	O	O
is	VBZ	O	O
over	RP	O	O
expressed	VBN	O	O
up	RP	O	O
to	TO	O	O
5-	JJ	O	O
and	CC	O	O
4-fold	JJ	O	O
,	,	O	O
by	IN	O	O
Tinospora	NNP	O	O
cordifolia	NN	O	O
and	CC	O	O
palmatine	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Next	JJ	O	O
to	TO	O	O
Glut-4	NNP	O	B-enzyme
,	,	O	O
the	DT	O	O
predominant	JJ	O	O
protein	NN	O	O
influencing	VBG	O	O
glucose	JJ	O	B-SUBSTRATE
metabolism	NN	O	O
is	VBZ	O	O
PPARalpha	NNP	O	O
and	CC	O	O
gamma	NNP	O	O
whose	WP$	O	O
expressions	NNS	O	O
were	VBD	O	O
also	RB	O	O
positively	RB	O	O
modulated	VBN	O	O
.	.	O	O

Further	RB	O	O
,	,	O	O
the	DT	O	O
inhibitors	NNS	O	O
of	IN	O	O
insulin	NN	O	O
pathway	NN	O	O
prevented	VBD	O	O
glucose	JJ	O	O
uptake	NN	O	O
mediated	VBN	O	O
by	IN	O	O
Tinospora	NNP	O	O
cordifolia	NN	O	O
and	CC	O	O
palmatine	NN	O	O
which	WDT	O	O
shows	VBZ	O	O
that	IN	O	O
the	DT	O	O
activity	NN	O	O
is	VBZ	O	O
majorly	RB	O	O
mediated	VBN	O	O
through	IN	O	O
insulin	NN	O	O
pathway	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
cytochrome	NN	O	O
P450	NNP	O	O
superfamily	RB	O	O
encompasses	VBZ	O	O
a	DT	O	O
diverse	JJ	O	O
group	NN	O	O
of	IN	O	O
enzymes	NNS	O	O
that	WDT	O	O
catalyze	VBP	O	O
the	DT	O	O
oxidation	NN	O	O
of	IN	O	O
various	JJ	O	O
substrates	NNS	O	O
.	.	O	O

The	DT	O	O
mouse	NN	O	O
CYP2J	NNP	O	B-enzyme
subfamily	RB	O	O
includes	VBZ	O	O
members	NNS	O	O
that	WDT	O	O
have	VBP	O	O
wide	JJ	O	O
tissue	NN	O	O
distribution	NN	O	O
and	CC	O	O
are	VBP	O	O
active	JJ	O	O
in	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
arachidonic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
(	(	O	O
AA	NNP	O	O
)	)	O	O
,	,	O	O
linoleic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
(	(	O	O
LA	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
other	JJ	O	O
lipids	NNS	O	O
and	CC	O	O
xenobiotics	NNS	O	O
.	.	O	O

The	DT	O	O
mouse	NN	O	O
Cyp2j	NNP	O	O
locus	NN	O	O
contains	NNS	O	O
seven	CD	O	O
genes	NNS	O	O
and	CC	O	O
three	CD	O	O
pseudogenes	NNS	O	O
located	VBN	O	O
in	IN	O	O
a	DT	O	O
contiguous	JJ	O	O
0.62	CD	O	O
megabase	NN	O	O
cluster	NN	O	O
on	IN	O	O
chromosome	NN	O	O
4	CD	O	O
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
four	CD	O	O
new	JJ	O	O
mouse	NN	O	O
CYP2J	NNP	O	O
isoforms	NNS	O	O
(	(	O	O
designated	VBN	O	O
CYP2J8	NNP	O	O
,	,	O	O
CYP2J11	NNP	O	O
,	,	O	O
CYP2J12	NNP	O	O
,	,	O	O
and	CC	O	O
CYP2J13	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
four	CD	O	O
cDNAs	NN	O	O
contain	NN	O	O
open	JJ	O	O
reading	NN	O	O
frames	NNS	O	O
that	WDT	O	O
encode	VBP	O	O
polypeptides	NNS	O	O
with	IN	O	O
62-84	JJ	O	O
%	NN	O	O
identity	NN	O	O
with	IN	O	O
the	DT	O	O
three	CD	O	O
previously	RB	O	O
identified	VBN	O	O
mouse	NN	O	O
CYP2Js	NNP	O	O
.	.	O	O

All	DT	O	O
four	CD	O	O
new	JJ	O	O
CYP2J	NNP	O	O
proteins	NNS	O	O
were	VBD	O	O
expressed	VBN	O	O
in	IN	O	O
Sf21	NNP	O	O
insect	JJ	O	O
cells	NNS	O	O
.	.	O	O

Each	DT	O	O
recombinant	NN	O	O
protein	NN	O	O
metabolized	VBD	O	O
AA	NNP	O	O
and	CC	O	O
LA	NNP	O	O
to	TO	O	O
epoxides	VB	O	O
and	CC	O	O
hydroxy	VB	O	O
derivatives	NNS	O	O
.	.	O	O

Specific	JJ	O	O
antibodies	NNS	O	O
,	,	O	O
mRNA	NN	O	O
probes	NNS	O	O
,	,	O	O
and	CC	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
primer	NN	O	O
sets	NNS	O	O
were	VBD	O	O
developed	VBN	O	O
for	IN	O	O
each	DT	O	O
mouse	NN	O	O
CYP2J	NNP	O	O
to	TO	O	O
examine	VB	O	O
their	PRP$	O	O
tissue	NN	O	O
distribution	NN	O	O
.	.	O	O

CYP2J8	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
,	,	O	O
liver	NN	O	O
,	,	O	O
and	CC	O	O
brain	NN	O	O
,	,	O	O
and	CC	O	O
protein	JJ	O	O
expression	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
and	CC	O	O
brain	NN	O	O
(	(	O	O
neuropil	JJ	O	O
)	)	O	O
.	.	O	O

CYP2J11	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
most	RBS	O	O
abundant	JJ	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
and	CC	O	O
heart	NN	O	O
,	,	O	O
with	IN	O	O
protein	NN	O	O
detected	VBN	O	O
primarily	RB	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
(	(	O	O
proximal	JJ	O	O
convoluted	VBN	O	O
tubules	NNS	O	O
)	)	O	O
,	,	O	O
liver	RB	O	O
,	,	O	O
and	CC	O	O
heart	NN	O	O
(	(	O	O
cardiomyocytes	NNS	O	O
)	)	O	O
.	.	O	O

CYP2J12	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
prominently	RB	O	O
present	JJ	O	O
in	IN	O	O
the	DT	O	O
brain	NN	O	O
,	,	O	O
and	CC	O	O
CYP2J13	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
multiple	JJ	O	O
tissues	NNS	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
highest	JJS	O	O
expression	NN	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
.	.	O	O

CYP2J12	NNP	O	O
and	CC	O	O
CYP2J13	NNP	O	O
protein	VBP	O	O
expression	NN	O	O
could	MD	O	O
not	RB	O	O
be	VB	O	O
determined	VBN	O	O
because	IN	O	O
the	DT	O	O
antibodies	NNS	O	O
developed	VBN	O	O
were	VBD	O	O
not	RB	O	O
immunospecific	JJ	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
four	CD	O	O
new	JJ	O	O
CYP2J	NNP	O	O
isoforms	NNS	O	O
might	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
AA	NNP	O	O
and	CC	O	O
LA	NNP	O	O
to	TO	O	O
bioactive	VB	O	O
lipids	NNS	O	O
in	IN	O	O
mouse	NN	O	O
hepatic	JJ	O	O
and	CC	O	O
extrahepatic	JJ	O	O
tissues	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Abstract	JJ	O	O
1	CD	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
and	CC	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
times	NNS	O	O
an	DT	O	O
inducer	NN	O	O
was	VBD	O	O
administered	VBN	O	O
and	CC	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
induction	NN	O	O
of	IN	O	O
hepatic	JJ	O	O
and	CC	O	O
intestinal	JJ	O	O
cytochrome	NN	O	B-enzyme
P450	NNP	O	I-enzyme
3A	CD	O	O
(	(	O	O
CYP3A	NNP	O	B-enzyme
)	)	O	O
in	IN	O	O
rats	NNS	O	O
using	VBG	O	O
dexamethasone	NN	O	B-SUBSTRATE
21-phosphate	JJ	O	I-SUBSTRATE
(	(	O	O
DEX-P	NNP	O	B-SUBSTRATE
)	)	O	O
and	CC	O	O
midazolam	$	O	B-SUBSTRATE
(	(	O	O
MDZ	NNP	O	B-SUBSTRATE
)	)	O	O
as	IN	O	O
an	DT	O	O
inducer	NN	O	O
and	CC	O	O
a	DT	O	O
substrate	NN	O	O
to	TO	O	O
CYP3A	NNP	O	B-enzyme
,	,	O	O
respectively	RB	O	O
.	.	O	O

2	CD	O	O
.	.	O	O

The	DT	O	O
number	NN	O	O
of	IN	O	O
times	NNS	O	O
DEX-P	NNP	O	O
was	VBD	O	O
administered	VBN	O	O
was	VBD	O	O
not	RB	O	O
a	DT	O	O
significant	JJ	O	O
factor	NN	O	O
in	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
either	CC	O	O
hepatic	JJ	O	O
or	CC	O	O
intestinal	JJ	O	O
CYP3A	NNP	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
administration	NN	O	O
of	IN	O	O
DEX-P	NNP	O	O
multiple	JJ	O	O
times	NNS	O	O
markedly	RB	O	O
decreased	VBD	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
DEX-P	NNP	O	O
by	IN	O	O
self-induction	NN	O	O
of	IN	O	O
CYP3A	NNP	O	O
.	.	O	O

3	CD	O	O
.	.	O	O

CYP3A	NNP	O	O
induction	NN	O	O
in	IN	O	O
the	DT	O	O
liver	NN	O	O
increased	VBD	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
DEX-P	NNP	O	O
,	,	O	O
whereas	VBZ	O	O
that	IN	O	O
in	IN	O	O
intestine	NN	O	O
showed	VBD	O	O
a	DT	O	O
mild	JJ	O	O
increase	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
induction	NN	O	O
level	NN	O	O
was	VBD	O	O
almost	RB	O	O
constant	JJ	O	O
regardless	NN	O	O
of	IN	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
DEX-P.	NNP	O	O
4	CD	O	O
.	.	O	O

Administration	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
DEX-P	NNP	O	O
showed	VBD	O	O
a	DT	O	O
temporal	JJ	O	O
increase	NN	O	O
in	IN	O	O
CYP3A	NNP	O	O
activity	NN	O	O
in	IN	O	O
both	DT	O	O
tissues	NNS	O	O
and	CC	O	O
the	DT	O	O
induction	NN	O	O
ratios	NNS	O	O
reached	VBD	O	O
maximum	JJ	O	O
values	NNS	O	O
at	IN	O	O
12	CD	O	O
h	NN	O	O
after	IN	O	O
DEX-P	NNP	O	O
administration	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
a	DT	O	O
mild	JJ	O	O
increase	NN	O	O
of	IN	O	O
CYP3A	NNP	O	O
activity	NN	O	O
,	,	O	O
which	WDT	O	O
lasted	VBD	O	O
for	IN	O	O
at	IN	O	O
least	JJS	O	O
48	CD	O	O
h	NN	O	O
,	,	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
both	DT	O	O
tissues	NNS	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
multiple	JJ	O	O
doses	NNS	O	O
.	.	O	O

5	CD	O	O
.	.	O	O

Some	DT	O	O
physiological	JJ	O	O
compounds	NNS	O	O
such	JJ	O	O
as	IN	O	O
cytokines	NNS	O	O
might	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
decreasing	VBG	O	O
the	DT	O	O
CYP3A	NNP	O	O
activity	NN	O	O
to	TO	O	O
maintain	VB	O	O
homeostasis	NN	O	O
of	IN	O	O
the	DT	O	O
body	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Dimethylarsinic	JJ	O	O
acid	NN	O	O
(	(	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
major	JJ	O	O
urinary	JJ	O	O
metabolite	NN	O	O
of	IN	O	O
inorganic	JJ	O	O
arsenic	NN	O	O
,	,	O	O
is	VBZ	O	O
weakly	JJ	O	O
cytotoxic	NN	O	O
,	,	O	O
whereas	IN	O	O
its	PRP$	O	O
reduced	JJ	O	O
form	NN	O	O
,	,	O	O
dimethylarsinous	JJ	O	O
acid	NN	O	O
(	(	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
)	)	O	O
,	,	O	O
is	VBZ	O	O
highly	RB	O	O
toxic	JJ	O	O
.	.	O	O

Although	IN	O	O
glutathione	JJ	O	B-enzyme
S-transferase	NNP	O	I-enzyme
omega	NN	O	O
1	CD	O	O
(	(	O	O
GSTO1	NNP	O	O
)	)	O	O
and	CC	O	O
arsenic	JJ	O	B-enzyme
methyltransferase	NN	O	I-enzyme
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
or	CC	O	O
thought	VBN	O	O
to	TO	O	O
catalyze	VB	O	O
DMAs	NNP	O	B-SUBSTRATE
(	(	O	O
V	NNP	O	O
)	)	O	O
reduction	NN	O	O
,	,	O	O
their	PRP$	O	O
role	NN	O	O
in	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
reduction	NN	O	O
in	IN	O	O
vivo	NN	O	O
,	,	O	O
or	CC	O	O
in	IN	O	O
cell	NN	O	O
extracts	NNS	O	O
is	VBZ	O	O
uncertain	JJ	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
to	TO	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
in	IN	O	O
rats	NNS	O	O
and	CC	O	O
in	IN	O	O
rat	NN	O	O
liver	NN	O	O
cytosol	NN	O	O
was	VBD	O	O
studied	VBN	O	O
to	TO	O	O
better	RBR	O	O
understand	VB	O	O
its	PRP$	O	O
mechanism	NN	O	O
.	.	O	O

To	TO	O	O
assess	VB	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
reduction	NN	O	O
in	IN	O	O
rats	NNS	O	O
,	,	O	O
a	DT	O	O
novel	JJ	O	O
procedure	NN	O	O
was	VBD	O	O
devised	VBN	O	O
based	VBN	O	O
on	IN	O	O
following	VBG	O	O
the	DT	O	O
accumulation	NN	O	O
of	IN	O	O
red	JJ	O	O
blood	NN	O	O
cell	NN	O	O
(	(	O	O
RBC	NNP	O	O
)	)	O	O
-bound	NN	O	O
dimethylarsenic	NN	O	O
(	(	O	O
DMAs	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
represents	VBZ	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
-injected	VBD	O	O
anesthetized	JJ	O	O
rats	NNS	O	O
.	.	O	O

These	DT	O	O
studies	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
rats	NNS	O	O
reduced	VBD	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
to	TO	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
to	TO	O	O
a	DT	O	O
significant	JJ	O	O
extent	NN	O	O
,	,	O	O
as	IN	O	O
in	IN	O	O
90	CD	O	O
min	NNS	O	O
31	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
injected	JJ	O	O
50	CD	O	O
mumol/kg	JJ	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
dose	NN	O	O
was	VBD	O	O
converted	VBN	O	O
to	TO	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
that	WDT	O	O
was	VBD	O	O
sequestered	VBN	O	O
by	IN	O	O
the	DT	O	O
circulating	NN	O	O
erythrocytes	VBZ	O	O
.	.	O	O

Pretreatment	NN	O	O
of	IN	O	O
rats	NNS	O	O
with	IN	O	O
glutathione	NN	O	O
(	(	O	O
GSH	NNP	O	O
)	)	O	O
depletors	NNS	O	O
(	(	O	O
phorone	NN	O	O
or	CC	O	O
BSO	NNP	O	O
)	)	O	O
delayed	VBD	O	O
the	DT	O	O
elimination	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
accumulation	NN	O	O
of	IN	O	O
RBC-bound	NNP	O	O
DMAs	NNP	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
indirect	JJ	O	O
methyltransferase	NN	O	O
inhibitor	NN	O	O
periodate-oxidized	JJ	O	O
adenosine	NN	O	O
was	VBD	O	O
without	IN	O	O
effect	NN	O	O
.	.	O	O

Assessment	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
-reducing	VBG	O	O
activity	NN	O	O
of	IN	O	O
rat	NN	O	O
liver	NN	O	O
cytosol	NN	O	O
revealed	VBD	O	O
that	IN	O	O
reduction	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
required	VBD	O	O
cytosolic	JJ	O	O
protein	NN	O	O
and	CC	O	O
GSH	NNP	O	O
and	CC	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
thiol	NN	O	O
reagents	NNS	O	O
,	,	O	O
GSSG	NNP	O	O
and	CC	O	O
dehydroascorbate	NN	O	O
.	.	O	O

Although	IN	O	O
thioredoxin	NN	O	O
reductase	NN	O	O
(	(	O	O
TRR	NNP	O	O
)	)	O	O
inhibitors	NNS	O	O
(	(	O	O
aurothioglucose	JJ	O	O
and	CC	O	O
Sb	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
)	)	O	O
inhibited	VBN	O	O
cytosolic	JJ	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
reduction	NN	O	O
,	,	O	O
recombinant	JJ	O	O
rat	NN	O	O
TRR	NNP	O	O
plus	CC	O	O
NADPH	NNP	O	O
,	,	O	O
alone	RB	O	O
or	CC	O	O
when	WRB	O	O
added	VBN	O	O
to	TO	O	O
the	DT	O	O
cytosol	NN	O	O
,	,	O	O
failed	VBD	O	O
to	TO	O	O
support	VB	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
reduction	NN	O	O
.	.	O	O

On	IN	O	O
ultrafiltration	NN	O	O
of	IN	O	O
the	DT	O	O
cytosol	NN	O	O
through	IN	O	O
a	DT	O	O
3	CD	O	O
kDa	NN	O	O
filter	NN	O	O
,	,	O	O
the	DT	O	O
reducing	VBG	O	O
activity	NN	O	O
in	IN	O	O
the	DT	O	O
retentate	NN	O	O
was	VBD	O	O
lost	VBN	O	O
but	CC	O	O
was	VBD	O	O
largely	RB	O	O
restored	VBN	O	O
by	IN	O	O
NADPH	NNP	O	O
.	.	O	O

Such	JJ	O	O
experiments	NNS	O	O
also	RB	O	O
suggested	VBD	O	O
that	IN	O	O
the	DT	O	O
reducing	VBG	O	O
enzyme	NN	O	O
was	VBD	O	O
larger	JJR	O	O
than	IN	O	O
100	CD	O	O
kDa	NNS	O	O
and	CC	O	O
was	VBD	O	O
not	RB	O	O
GSTO1	NNP	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
reduction	NN	O	O
of	IN	O	O
DMAs	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
to	TO	O	O
the	DT	O	O
highly	RB	O	O
toxic	JJ	O	O
DMAs	NNP	O	O
(	(	O	O
III	NNP	O	O
)	)	O	O
in	IN	O	O
rats	NNS	O	O
and	CC	O	O
rat	VB	O	O
liver	JJR	O	O
cytosol	NN	O	O
is	VBZ	O	O
a	DT	O	O
GSH-dependent	JJ	O	O
enzymatic	JJ	O	O
process	NN	O	O
,	,	O	O
yet	CC	O	O
its	PRP$	O	O
mechanism	NN	O	O
remains	VBZ	O	O
uncertain	JJ	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Ferredoxin	NN	O	B-enzyme
1	CD	O	I-enzyme
(	(	O	O
FDX1	NNP	O	B-enzyme
;	:	O	O
adrenodoxin	NN	O	B-enzyme
)	)	O	O
is	VBZ	O	O
an	DT	O	O
iron-sulfur	JJ	O	O
protein	NN	O	O
that	WDT	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
various	JJ	O	O
metabolic	JJ	O	O
processes	NNS	O	O
,	,	O	O
including	VBG	O	O
steroid	JJ	O	B-PRODUCT-OF
hormone	NN	O	I-PRODUCT-OF
synthesis	NN	O	O
in	IN	O	O
mammalian	JJ	O	O
tissues	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
transcriptional	JJ	O	O
regulation	NN	O	O
of	IN	O	O
FDX1	NNP	O	O
in	IN	O	O
ovarian	JJ	O	O
granulosa	NN	O	O
cells	NNS	O	O
.	.	O	O

Previously	RB	O	O
,	,	O	O
we	PRP	O	O
reported	VBD	O	O
that	IN	O	O
the	DT	O	O
NR5A	NNP	O	O
family	NN	O	O
,	,	O	O
including	VBG	O	O
steroidogenic	JJ	O	O
factor-1	JJ	O	O
(	(	O	O
SF-1	NNP	O	O
)	)	O	O
and	CC	O	O
liver	JJ	O	O
receptor	NN	O	O
homolog-1	NN	O	O
could	MD	O	O
induce	VB	O	O
differentiation	NN	O	O
of	IN	O	O
human	JJ	O	O
mesenchymal	JJ	O	O
stem	NN	O	O
cells	NNS	O	O
(	(	O	O
hMSCs	NN	O	O
)	)	O	O
into	IN	O	O
steroidogenic	JJ	O	O
cells	NNS	O	O
.	.	O	O

A	DT	O	O
ChIP	NNP	O	O
assay	NN	O	O
showed	VBD	O	O
that	IN	O	O
SF-1	NNP	O	O
could	MD	O	O
bind	VB	O	O
to	TO	O	O
the	DT	O	O
FDX1	NNP	O	O
promoter	NN	O	O
in	IN	O	O
differentiated	JJ	O	O
hMSCs	NN	O	O
.	.	O	O

Luciferase	NNP	O	O
reporter	NN	O	O
assays	NNS	O	O
showed	VBD	O	O
that	IN	O	O
transcription	NN	O	O
of	IN	O	O
FDX1	NNP	O	O
was	VBD	O	O
synergistically	RB	O	O
activated	VBN	O	O
by	IN	O	O
the	DT	O	O
NR5A	NNP	O	O
family	NN	O	O
and	CC	O	O
8Br-cAMP	JJ	O	O
treatment	NN	O	O
through	IN	O	O
two	CD	O	O
SF-1	JJ	O	O
binding	NN	O	O
sites	NNS	O	O
and	CC	O	O
a	DT	O	O
CRE-like	JJ	O	O
sequence	NN	O	O
in	IN	O	O
a	DT	O	O
human	JJ	O	O
ovarian	JJ	O	O
granulosa	NN	O	O
cell	NN	O	O
line	NN	O	O
,	,	O	O
KGN	NNP	O	O
.	.	O	O

Knockdown	NNP	O	O
of	IN	O	O
FDX1	NNP	O	O
attenuated	VBD	O	O
progesterone	NN	O	O
production	NN	O	O
in	IN	O	O
KGN	NNP	O	O
cells	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
transcription	NN	O	O
of	IN	O	O
FDX1	NNP	O	B-enzyme
is	VBZ	O	O
regulated	VBN	O	O
by	IN	O	O
the	DT	O	O
NR5A	NNP	O	O
family	NN	O	O
and	CC	O	O
cAMP	NN	O	O
signaling	NN	O	O
,	,	O	O
and	CC	O	O
participates	NNS	O	O
in	IN	O	O
steroid	JJ	O	B-PRODUCT-OF
hormone	NN	O	O
production	NN	O	O
in	IN	O	O
ovarian	JJ	O	O
granulosa	NN	O	O
cells	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Cytochrome	NNP	O	B-enzyme
P450	NNP	O	I-enzyme
epoxygenase	NN	O	O
2J2	CD	O	O
(	(	O	O
CYP2J2	NNP	O	B-enzyme
)	)	O	O
metabolizes	VBZ	O	O
arachidonic	JJ	O	B-SUBSTRATE
acids	NNS	O	I-SUBSTRATE
to	TO	O	O
form	VB	O	O
epoxyeicosatrienoic	JJ	O	B-PRODUCT-OF
acids	NNS	O	I-PRODUCT-OF
(	(	O	O
EETs	NNP	O	B-PRODUCT-OF
)	)	O	O
,	,	O	O
which	WDT	O	O
possess	VBP	O	O
various	JJ	O	O
beneficial	JJ	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
cardiovascular	JJ	O	O
system	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
whether	IN	O	O
increasing	VBG	O	O
EETs	NNP	O	B-PRODUCT-OF
production	NN	O	O
by	IN	O	O
CYP2J2	NNP	O	B-enzyme
overexpression	NN	O	O
in	IN	O	O
vivo	NN	O	O
could	MD	O	O
prevent	VB	O	O
abdominal	JJ	O	O
aortic	JJ	O	O
aneurysm	NN	O	O
(	(	O	O
AAA	NNP	O	O
)	)	O	O
remains	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
recombinant	JJ	O	O
adeno-associated	JJ	O	O
virus	NN	O	O
(	(	O	O
rAAV	NN	O	O
)	)	O	O
-mediated	VBD	O	O
CYP2J2	NNP	O	O
overexpression	NN	O	O
on	IN	O	O
angiotensin	NN	O	O
(	(	O	O
Ang	NNP	O	O
)	)	O	O
II-induced	NNP	O	O
AAA	NNP	O	O
in	IN	O	O
apoE-deficient	JJ	O	O
mice	NN	O	O
.	.	O	O

rAAV-CYP2J2	JJ	O	O
delivery	NN	O	O
led	VBD	O	O
to	TO	O	O
an	DT	O	O
abundant	JJ	O	O
aortic	JJ	O	O
CYP2J2	NNP	O	O
expression	NN	O	O
and	CC	O	O
increased	JJ	O	O
EETs	NNP	O	O
generation	NN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
shown	VBN	O	O
that	IN	O	O
CYP2J2	NNP	O	O
overexpression	NN	O	O
attenuated	VBD	O	O
matrix	JJ	O	O
metalloproteinase	NN	O	O
expression	NN	O	O
and	CC	O	O
activity	NN	O	O
,	,	O	O
elastin	JJ	O	O
degradation	NN	O	O
,	,	O	O
and	CC	O	O
AAA	NNP	O	O
formation	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
reduced	JJ	O	O
aortic	JJ	O	O
inflammation	NN	O	O
and	CC	O	O
macrophage	NN	O	O
infiltration	NN	O	O
.	.	O	O

In	IN	O	O
cultured	JJ	O	O
vascular	JJ	O	O
smooth	JJ	O	O
muscle	NN	O	O
cells	NNS	O	O
(	(	O	O
VSMCs	NNP	O	O
)	)	O	O
,	,	O	O
rAAV-mediated	JJ	O	O
CYP2J2	NNP	O	O
overexpression	NN	O	O
and	CC	O	O
EETs	NNP	O	O
markedly	RB	O	O
suppressed	VBD	O	O
Ang	NNP	O	O
II-induced	NNP	O	O
inflammatory	JJ	O	O
cytokine	NN	O	O
expression	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
overexpressed	VBD	O	O
CYP2J2	NNP	O	O
and	CC	O	O
EETs	NNP	O	O
inhibited	VBD	O	O
Ang	NNP	O	O
II-induced	NNP	O	O
macrophage	NN	O	O
migration	NN	O	O
in	IN	O	O
a	DT	O	O
VSMC-macrophage	JJ	O	O
coculture	NN	O	O
system	NN	O	O
.	.	O	O

We	PRP	O	O
further	RB	O	O
indicated	VBD	O	O
that	IN	O	O
these	DT	O	O
protective	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
mediated	VBN	O	O
by	IN	O	O
peroxisome	JJ	O	O
proliferator-activated	JJ	O	O
receptor	NN	O	O
(	(	O	O
PPAR	NNP	O	O
)	)	O	O
gamma	VBZ	O	O
activation	NN	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
provide	VBP	O	O
evidence	NN	O	O
that	IN	O	O
rAAV-mediated	JJ	O	O
CYP2J2	NNP	O	O
overexpression	NN	O	O
prevents	NNS	O	O
AAA	NNP	O	O
development	NN	O	O
which	WDT	O	O
is	VBZ	O	O
likely	JJ	O	O
via	IN	O	O
PPARgamma	NNP	O	O
activation	NN	O	O
and	CC	O	O
anti-inflammatory	JJ	O	O
action	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
increasing	VBG	O	O
EETs	NNP	O	O
levels	NNS	O	O
could	MD	O	O
be	VB	O	O
considered	VBN	O	O
as	IN	O	O
a	DT	O	O
potential	JJ	O	O
strategy	NN	O	O
to	TO	O	O
prevent	VB	O	O
and	CC	O	O
treat	VB	O	O
AAA	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Human	NNP	O	O
Organic	NNP	O	O
Anion	NNP	O	O
Transporting	NNP	O	O
Polypeptide	NNP	O	O
2B1	CD	O	O
(	(	O	O
OATP2B1	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
membrane	NN	O	O
transporter	NN	O	O
that	WDT	O	O
facilitates	VBZ	O	O
the	DT	O	O
cellular	JJ	O	O
uptake	NN	O	O
of	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
endogenous	JJ	O	O
compounds	NNS	O	O
and	CC	O	O
drugs	NNS	O	O
.	.	O	O

OATP2B1	NNP	O	O
is	VBZ	O	O
widely	RB	O	O
expressed	VBN	O	O
in	IN	O	O
tissues	NNS	O	O
including	VBG	O	O
the	DT	O	O
small	JJ	O	O
intestine	NN	O	O
,	,	O	O
liver	RB	O	O
,	,	O	O
kidney	NN	O	O
,	,	O	O
placenta	NN	O	O
,	,	O	O
heart	NN	O	O
,	,	O	O
skeletal	JJ	O	O
muscle	NN	O	O
and	CC	O	O
platelets	NNS	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
it	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
that	IN	O	O
differential	JJ	O	O
promoter	NN	O	O
usage	NN	O	O
in	IN	O	O
tissues	NNS	O	O
results	NNS	O	O
in	IN	O	O
expression	NN	O	O
of	IN	O	O
five	CD	O	O
OATP2B1	NNP	O	O
transcriptional	JJ	O	O
start	NN	O	O
site	NN	O	O
variants	NNS	O	O
which	WDT	O	O
utilize	VBP	O	O
distinct	NNS	O	O
first	JJ	O	O
exons	NNS	O	O
but	CC	O	O
share	NN	O	O
common	JJ	O	O
subsequent	JJ	O	O
exons	NNS	O	O
.	.	O	O

These	DT	O	O
variants	NNS	O	O
are	VBP	O	O
expected	VBN	O	O
to	TO	O	O
encode	VB	O	O
either	CC	O	O
a	DT	O	O
full	JJ	O	O
length	NN	O	O
(	(	O	O
OATP2B1-FL	NNP	O	O
)	)	O	O
or	CC	O	O
shortened	VBN	O	O
protein	IN	O	O
lacking	VBG	O	O
22	CD	O	O
N-terminus	JJ	O	O
amino	NN	O	O
acids	NNS	O	O
(	(	O	O
OATP2B-Short	NNP	O	O
)	)	O	O
.	.	O	O

Little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
regarding	VBG	O	O
the	DT	O	O
transport	NN	O	O
activity	NN	O	O
and	CC	O	O
regulation	NN	O	O
of	IN	O	O
OATP2B1	NNP	O	O
variants	NNS	O	O
with	IN	O	O
N-terminus	NNP	O	O
truncation	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
using	VBG	O	O
absolute	JJ	O	O
quantitative	JJ	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
we	PRP	O	O
find	VBP	O	O
the	DT	O	O
full	JJ	O	O
length	NN	O	O
variant	NN	O	O
is	VBZ	O	O
the	DT	O	O
major	JJ	O	O
form	NN	O	O
expressed	VBN	O	O
in	IN	O	O
duodenum	NN	O	O
but	CC	O	O
the	DT	O	O
short	JJ	O	O
variant	NN	O	O
predominates	NNS	O	O
in	IN	O	O
liver	NN	O	O
.	.	O	O

Using	VBG	O	O
a	DT	O	O
transient	NN	O	O
heterologous	JJ	O	O
cell	NN	O	O
expression	NN	O	O
system	NN	O	O
,	,	O	O
we	PRP	O	O
find	VBP	O	O
that	IN	O	O
the	DT	O	O
transport	NN	O	O
activities	NNS	O	O
of	IN	O	O
the	DT	O	O
short	JJ	O	B-enzyme
OATP2B1	NNP	O	I-enzyme
variant	NN	O	O
towards	NNS	O	O
substrates	VBZ	O	O
estrone	JJ	O	B-SUBSTRATE
sulfate	NN	O	I-SUBSTRATE
and	CC	O	O
rosuvastatin	NN	O	B-SUBSTRATE
are	VBP	O	O
similar	JJ	O	O
to	TO	O	O
the	DT	O	O
well-characterized	JJ	O	O
full	JJ	O	O
length	NN	O	O
variant	NN	O	O
.	.	O	O

Transcriptional	JJ	O	O
activity	NN	O	O
screening	NN	O	O
of	IN	O	O
the	DT	O	O
liver	NN	O	O
enriched	VBD	O	O
OATP2B1	NNP	O	O
variant	JJ	O	O
promoter	NN	O	O
identified	VBN	O	O
hepatocyte	JJ	O	O
nuclear	JJ	O	O
factor	NN	O	O
4	CD	O	O
alpha	NN	O	O
(	(	O	O
HNF4alpha	NNP	O	O
)	)	O	O
as	IN	O	O
a	DT	O	O
novel	JJ	O	O
transacting	NN	O	O
factor	NN	O	O
.	.	O	O

With	IN	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
in	IN	O	O
silico	NN	O	O
screening	NN	O	O
,	,	O	O
promoter	NN	O	O
mutation	NN	O	O
in	IN	O	O
cell-based	JJ	O	O
reporter	NN	O	O
assays	NNS	O	O
,	,	O	O
siRNA	VBP	O	O
knockdown	VBN	O	O
and	CC	O	O
chromatin	JJ	O	O
immunoprecipitation	NN	O	O
studies	NNS	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
a	DT	O	O
functional	JJ	O	O
HNF4alpha	NNP	O	O
binding	VBG	O	O
site	NN	O	O
close	RB	O	O
to	TO	O	O
the	DT	O	O
transcription	NN	O	O
start	NN	O	O
site	NN	O	O
(	(	O	O
-17	JJ	O	O
to	TO	O	O
-4	VB	O	O
bp	NN	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
major	JJ	O	O
OATP2B1	NNP	O	O
protein	NN	O	O
form	NN	O	O
in	IN	O	O
liver	NN	O	O
is	VBZ	O	O
transport	JJ	O	O
competent	NN	O	O
and	CC	O	O
its	PRP$	O	O
hepatic	JJ	O	O
expression	NN	O	O
is	VBZ	O	O
regulated	VBN	O	O
by	IN	O	O
HNF4alpha	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Cisplatin	NNP	O	O
(	(	O	O
cDDP	NN	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
anti-cancer	JJ	O	O
drug	NN	O	O
used	VBN	O	O
in	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
malignancies	NNS	O	O
including	VBG	O	O
testicular	NN	O	O
,	,	O	O
ovarian	JJ	O	O
,	,	O	O
cervical	JJ	O	O
,	,	O	O
bladder	NN	O	O
,	,	O	O
lung	NN	O	O
,	,	O	O
head	NN	O	O
,	,	O	O
and	CC	O	O
neck	NN	O	O
cancers	NNS	O	O
.	.	O	O

Its	PRP$	O	O
use	NN	O	O
is	VBZ	O	O
limited	VBN	O	O
by	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
resistance	NN	O	O
,	,	O	O
often	RB	O	O
rationalized	VBN	O	O
via	IN	O	O
effects	NNS	O	O
on	IN	O	O
cellular	JJ	O	O
uptake	NN	O	O
.	.	O	O

It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
claimed	VBN	O	O
that	IN	O	O
hCTR1	NN	O	B-enzyme
,	,	O	O
the	DT	O	O
human	JJ	O	B-enzyme
high	JJ	O	I-enzyme
affinity	NN	O	O
copper	NN	O	O
transporter	NN	O	O
,	,	O	O
is	VBZ	O	O
the	DT	O	O
major	JJ	O	O
entry	NN	O	O
pathway	NN	O	O
for	IN	O	O
cDDP	NN	O	B-SUBSTRATE
and	CC	O	O
related	JJ	O	O
drugs	NNS	O	O
via	IN	O	O
a	DT	O	O
mechanism	NN	O	O
that	IN	O	O
mimics	NNS	O	O
copper	NN	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
an	DT	O	O
unexpected	JJ	O	O
property	NN	O	O
of	IN	O	O
hCTR1	NN	O	O
,	,	O	O
a	DT	O	O
highly	RB	O	O
selective	JJ	O	O
copper	NN	O	O
(	(	O	O
I	PRP	O	O
)	)	O	O
transporter	NN	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
uptake	JJ	O	O
rates	NNS	O	O
of	IN	O	O
copper	NN	O	O
with	IN	O	O
cDDP	NN	O	O
(	(	O	O
and	CC	O	O
several	JJ	O	O
analogs	NNS	O	O
)	)	O	O
into	IN	O	O
HEK293	NNP	O	O
cells	NNS	O	O
over-expressing	JJ	O	O
wild-type	JJ	O	O
or	CC	O	O
mutant	JJ	O	O
hCTR1	NN	O	O
,	,	O	O
mouse	NN	O	O
embryonic	JJ	O	O
fibroblasts	NNS	O	O
(	(	O	O
mefs	NNS	O	O
)	)	O	O
that	WDT	O	O
do	VBP	O	O
or	CC	O	O
do	VB	O	O
not	RB	O	O
express	VB	O	O
CTR1	NNP	O	O
,	,	O	O
and	CC	O	O
human	JJ	O	O
ovarian	JJ	O	O
tumor	NN	O	O
cells	NNS	O	O
,	,	O	O
sensitive	JJ	O	O
or	CC	O	O
resistant	JJ	O	O
to	TO	O	O
cDDP	VB	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
also	RB	O	O
compared	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
extracellular	JJ	O	O
copper	NN	O	O
,	,	O	O
which	WDT	O	O
causes	VBZ	O	O
regulatory	JJ	O	O
endocytosis	NN	O	O
of	IN	O	O
hCTR1	NN	O	O
,	,	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
cDDP	NN	O	O
.	.	O	O

We	PRP	O	O
confirm	VBP	O	O
the	DT	O	O
correlation	NN	O	O
between	IN	O	O
higher	JJR	O	O
hCTR1	NN	O	B-enzyme
levels	NNS	O	O
and	CC	O	O
higher	JJR	O	O
Pt-drug	NNP	O	O
uptake	NN	O	O
in	IN	O	O
tumor	NN	O	O
cells	NNS	O	O
sensitive	JJ	O	O
to	TO	O	O
the	DT	O	O
drug	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
hCTR1	NN	O	O
is	VBZ	O	O
not	RB	O	O
the	DT	O	O
major	JJ	O	O
entry	NN	O	O
route	NN	O	O
of	IN	O	O
platinum-drugs	NNS	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
copper	NN	O	O
transporter	NN	O	O
is	VBZ	O	O
not	RB	O	O
internalized	VBN	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
extracellular	JJ	O	O
drug	NN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
the	DT	O	O
major	JJ	O	O
entry	NN	O	O
pathway	NN	O	O
for	IN	O	O
platinum-drugs	NN	O	O
is	VBZ	O	O
not	RB	O	O
saturable	JJ	O	O
at	IN	O	O
relevant	JJ	O	O
concentrations	NNS	O	O
and	CC	O	O
not	RB	O	O
protein-mediated	JJ	O	O
.	.	O	O

Clinical	JJ	O	O
trials	NNS	O	O
have	VBP	O	O
been	VBN	O	O
initiated	VBN	O	O
that	IN	O	O
depend	VBP	O	O
upon	IN	O	O
regulating	VBG	O	O
membrane	NN	O	O
levels	NNS	O	O
of	IN	O	O
hCTR1	NN	O	O
.	.	O	O

If	IN	O	O
reduced	VBN	O	O
drug	NN	O	O
uptake	NN	O	O
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
factor	NN	O	O
in	IN	O	O
resistance	NN	O	O
,	,	O	O
hCTR1	NN	O	O
is	VBZ	O	O
unlikely	JJ	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
productive	JJ	O	O
target	NN	O	O
in	IN	O	O
attempts	NNS	O	O
to	TO	O	O
enhance	VB	O	O
efficacy	NN	O	O
,	,	O	O
although	IN	O	O
the	DT	O	O
proteins	NNS	O	O
involved	VBN	O	O
in	IN	O	O
copper	NN	O	O
homeostasis	NN	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
.	.	O	O
